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Aldehyde dehydrogenase (ALDH) enzymes are key for the metabolism and
detoxification of aldehydes and biosynthesis of molecules critical for cellular
function. ALDHs are highly expressed in stem cells and are considered
reliable experimental markers of cancer initiating cells. ALDHs are key
enzymes for the bioactivation of 5-nitrofurans (5-NFNs) but downstream
effects of this interaction on ALDH-mediated metabolic pathways have not
been characterised. 5-NFN compounds have anti-bacterial and
anti-trypanosome activity driven by bacterial- and parasite-specific
nitroreductases. Despite recommendation of the 5-NFN compound, nifurtimox
as a World Health Organisation essential medicine, this compound produces
a multitude of side effects in humans, similar to those resulting from exposure
to disulfiram, a known ALDH inhibitor. The 5-NFNs, nifurtimox and
nifuroxazide are both promising candidates for repurposing as neuroblastoma
and melanoma anti-cancer therapeutics, respectively. Results chapter 1 of
this thesis explored the hypothesis that 5-NFNs are competitive substrates for
mammalian ALDH enzymes in vivo and that this interaction drives the
side-effects of 5-NFNs. Recombinant enzymes, murine liver extracts,
precision cut liver slices and in vivo models were utilised to explore the effects
of 5-NFNs in the liver, that highly expresses ALDH enzymes. The 5-NFNs are
found to act as competitive substrates for the dehydrogenase and esterase
activities of acetaldehyde-detoxifying ALDH enzymes and differentially inhibit
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ALDH activity in mammalian liver. Additionally, the human hepatoma cell line,
HepG2 was discovered to be sensitive to 5-NFNs and the addition of ALDH
substrates alters sensitivity to 5-NFNs. A study to determine the effect of
5-NFN treatment on ALDH metabolic pathways indicates that circulating
levels of acetaldehyde are increased in the blood of ethanol- and
nitrofuran-treated Aldh1b1-/- mice. Acetaldehyde is a DNA-damaging agent
and carcinogen that cells are exposed to from endogenous and exogenous
sources: However, quantitation of acetaldehyde levels in plasma presents
technical difficulties. With the aim of initiating set up of a short-chain aldehyde
detection method that could be applied to the quantification of aldehydes in
blood and cell lysates, results chapter 2 describes the development of
acetaldehyde derivatisation methods coupled with comparison of Orbitrap
high-resolution and triple Quadrupole mass spectrometry detection of
aldehyde derivatives. Given that ALDH1A3 is expressed in cancer initiating
cells and the 5-NFN, nifuroxazide targets ALDHhigh populations, the effect of
ALDH1A3 expression in ALDHhigh cells in relation to the long-chain
aldehyde, and main ALDH1A3 substrate, retinaldehyde was explored.
Results chapter 3 explores consequences of ALDH1A3 expression through
transcriptomic analysis. To investigate the importance of ALDH1A3 activity on
gene expression regulation in melanoma, transcriptomes of ALDHhigh,
ALDHlow and ALDH1A3null melanoma populations were compared.
Comparison of ALDHhigh- and ALDHlow-expressing A375 melanoma cell
populations revealed a MITFlow-neural crest stem cell-(NCSC) high
transcriptional signature that is driven through retinoic acid receptor (RXRG)
signalling. This signature is differentially expressed in the ALDHhigh
population compared to ALDHlow and is associated with minimal residual
disease in melanoma; this highlights a therapeutic opportunity for developing
an anti-cancer strategy that is specific to melanoma minimal residual disease
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by targeting ALDHhigh populations with nifuroxazide and inhibitors of
retinaldehyde/retinoic acid metabolism. Collectively, understanding the
ALDH:5-NFN enzyme-drug interaction and its downstream consequences on
aldehyde-metabolising pathways informs about the mechanisms of
5-NFN-induced side effects but also has potential to be exploited for
chemotherapeutic targeting of the ALDH-expressing minimal residual disease
population in melanoma. This highlights ALDH as an important drug target in




Every day, our bodies are exposed to chemical molecules that can be
beneficial or detrimental to our health. One group of molecules that can have
good and bad effects on the cells in our body are aldehydes. Aldehydes are
small molecules that our bodies can produce on their own but are also
present in the environment. Acetaldehyde is one type of aldehyde that is
produced by our own bodies during normal metabolism but is found at high
concentrations in alcohol and in air pollution. Aldehydes are very small and
reactive which means they can bind to DNA and proteins within cells, where
they can cause damage and cause cells to die. To prevent acetaldehyde from
reaching high concentrations within our bodies, our liver expresses high levels
of a protein called ALDH. This protein converts acetaldehyde to acetic acid.
Acetic acid is otherwise known as vinegar, it is non-toxic to cells which means
that protein and DNA damage does not occur. This is great news for the
majority of people but 8% of people worldwide have a form of the ALDH gene
called ALDH2*2. This gene codes for a less functional protein which converts
acetaldehyde to acetic acid much slower or not at all. This means that when
cells become exposed to acetaldehyde, it is not detoxified and levels of it rise
in cells, causing cells to die. With my research I have discovered that a class
of drugs called 5-nitrofurans prevent the ALDH protein from breaking down
acetaldehyde. This is bad news for people with the ALDH2*2 form of the gene
because they are already unable to breakdown acetaldehyde fast enough to
v
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prevent damage. Levels of acetaldehyde rise in the blood when cells are
exposed to alcohol and 5-nitrofurans at the same time and so I set up a
scientific method to robustly measure the amount of different aldehydes that
are in blood. Alcohol and 5-nitrofurans cause levels of acetaldehyde to rise in
normal mice, but this effect is enhanced when the ALDH1B1 protein is
removed in mice. This means that people who are undergoing treatment with
5-nitrofurans might suffer the damaging effects of acetaldehyde when they
drink alcohol. 5-nitrofuran drugs can be used to kill cancer cells that have high
levels of ALDH enzyme. I wanted to discover why ALDH enzymes are
expressed in cancer cells, what the differences were between cancer cells
that had lots of ALDH protein and cancer cells that did not, and what would
happen to the genetic instructions inside the cell if ALDH was removed. I
discovered that ALDH and the molecule it generates, called retinaldehyde are
responsible for maintaining skin cancer cells in a state that is resistance to
chemotherapy. These results mean that we now have a better understanding
of how aldehydes can be altered within our bodies with 5-nitrofurans and how
this might be the reason why 5-nitrofurans have damaging effects on both
healthy and cancerous cells.
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amu atomic mass unit
BAAA BODIPY™-aminoacetaldehyde
BAAA-DA BODIPY™-aminoacetaldehyde diethyl acetal
bp base pair
cDNA complementary deoxyribonucleic acid
CE collision energy
coA coenzyme A
cps counts per second
cts counts
CXP cell exit potential
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DEAB diethylamino-benzaldehyde
DEG differentially expressed gene
DIMATE dimethyl ampal thiolester
DNPH 2,4-dinitrophenylhydrazine
ds double stranded
ECACC European Collection of Authenticated Cell Cultures
ESI electrospray ionisation
FA-DNPH formaldehyde-2,4-DNPH
FACS fluorescence activated cell sorting
FDR false discovery rate
GAPDH glyceraldehyde-3-phosphate dehydrogenase
GSEA gene set enrichment analysis
HPLC-MS high-performance liquid chromatography
HSA highest single agent
kb kilobase
LC liquid chromatography
LC-MS/MS liquid chromatography tandem mass spectrometry
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MeCN acetonitrile
min minutes
mRNA messenger ribonucleic acid
MS mass spectrometry
m/z mass-to-charge ratio
NAD+ nicotinamide adenine dinucleotide (oxidised)
NADH nicotinamide adenine dinucleotide (reduced)
NADP+ nicotinamide adenine dinucleotide phosphate (oxidised)
NADPH nicotinamide adenine dinucleotide phosphate (reduced)
NCSC neural crest stem cell
NAZ nifuroxazide






PCR polymerase chain reaction
PF pass-filter
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RA retinoic acid
RAR retinoic acid receptor
RXR retinoid X receptor
RXRG retinoid X receptor gamma
RARE retinoic acid response element
rpm revolutions per minute
RNA ribonucleic acid
ROS reactive oxygen species
RT room temperature
SNP single nucleotide polymorphism
SPE solid phase extraction
TCGA The Cancer Genome Atlas
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1.1 Aldehyde Dehydrogenases and Aldehyde
Metabolism
Aldehyde metabolism is dependent on the activities of the Aldehyde
Dehydrogenase (ALDH) enzyme superfamily (EC 1.2.1.3; systematic name:
aldehyde:NAD(P)+ oxidoreductase). The nineteen enzymes that constitute
this family are known for their capacity to metabolise aldehydes that are
relevant to both physiology and pathophysiology. Although a diverse enzyme
class, ALDHs have been highly conserved throughout evolution, highlighting
the importance of ALDH and particularly aldehyde metabolism in maintaining
cellular function.
1.1.1 Substrates
ALDH enzymes share common catalytic activities but each ALDH isoform
demonstrates distinct substrate specificities (Table 1.1). The number of
molecules that have been identified as substrates of enzymes in this class is
considerable and so it is unsurprising that ALDHs have diverse functions in
maintaining cellular states (Marchitti et al., 2008). Aldehydes comprise the
largest class of substrates for the ALDH enzymes. Pathophysiologically, the
metabolism of aldehydes by ALDH dehydrogenase activity is of central
importance to detoxification processes. Historically, the focus of aldehyde
biology has been largely directed toward these detoxification functions of
ALDH enzymes. However, recent developments and improved tools for
tracing of aldehydes, aldehyde precursors and the biological adducts that
aldehydes produce including probe-based imaging and mass spectrometric
techniques have uncovered a new field of interest in aldehyde biology,
providing new ways to research long-standing questions such as the origin
and detoxification of DNA damage and functional importance of ALDH
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expression particularly in cancer.
As ALDH enzymes differ in their relative specificity for aldehyde
substrates, some ALDHs are involved preferentially in mediating the
pathophysiological effects of aldehydes, whereas others are required to
generate physiologically important endogenous cell signalling molecules from
aldehyde precursors (Marchitti et al., 2008). There is some degree of overlap
between these two seemingly opposing functions and most ALDHs catalyse
metabolism of several substrates, exposure to which can be modulated on a
tissue-specific level.
The dehydrogenase activity of ALDH is well-described and endogenous
aldehyde substrates have been identified but ALDH enzymes also possess an
esterase function (Sidhu and Blair, 1975; Blackwell et al., 1983). ALDH1 and
ALDH2 isoforms have been shown to catalyse ester hydrolysis of
4-nitrophenyl acetate (4-NPA) to 4-nitrophenol (4-NP) (Morgan and Hurley,
2015). Although there are currently no discovered endogenous or xenobiotic
ester substrates of ALDH enzymes in vivo, ALDHs are involved in xenobiotic
metabolism and a nitroglycerin reductase function of ALDHs is exemplified by
the ALDH-dependent bioactivation of nitroglycerin to NO and other nitrates
(Chen et al., 2002; Beretta et al., 2008; D’Souza et al., 2011).
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Table 1.1: Key Substrates of ALDH Enzymes
Substrate ALDH Km (µM) Reference
Acetaldehyde ALDH2 0.2 Klyosov et al. (1996) and
Klyosov (1996)
ALDH2 3.2 Stagos et al. (2010)
ALDH1B1 55 Stagos et al. (2010)
ALDH1A1 180 Klyosov et al. (1996)
ALDH8A1 10240 Lin and Napoli (2000)
ALDH9A1 -
All-trans Retinaldehyde ALDH1A1 11.6 Gagnon et al. (2003)
26.8 Jackson et al. (2015)
ALDH1A2 0.66 Gagnon et al. (2002)
ALDH1A3 0.2 Graham et al. (2006)
ALDH8A1 - Lin and Napoli (2000)
9-cis Retinaldehyde ALDH1A1 3.59 Gagnon et al. (2003)
ALDH1A2 2.25 Gagnon et al. (2002)
ALDH1A3 -
ALDH8A1 3.15 Lin and Napoli (2000)
13-cis Retinaldehyde ALDH1A2 0.62 Gagnon et al. (2002)
Enzymes highlighted in green are the major ALDH isoform involved in metabolism of
each substrate. Information from sources Marchitti et al. (2008); Singh et al. (2015);
Wang et al. (2009) and as designated in the table.
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1.1.2 Acetaldehyde Sources
Cellular acetaldehyde originates from endogenous and exogenous sources.
Sources of acetaldehyde are plentiful in the environment: Alongside other
aldehydes, acetaldehyde is produced upon hydrocarbon combustion in
vehicle motors and cigarette smoke and is a component of industrial dyes,
plastics and rubber. Bacteria in the oral cavity and gut produce acetaldehyde
through pyruvate decarboxylase catalysis of pyruvate to acetaldehyde
(Chandra Raj et al., 2001). In addition to effects of microbiotic metabolism, it
is claimed that endogenous acetaldehyde can arise in cells through
catabolism of alanine and the degradation of deoxyribose PO4 (Tacconi et al.,
2017) but evidence for this in mammalian systems is lacking. Acetaldehyde
burden in cells is also affected by dietary factors. Consumption of foods,
particularly those that are fermented, is a key route of exposure to
acetaldehyde. The most well-documented form of exposure to acetaldehyde
arises through ethanol metabolism. Ethanol is metabolised predominantly in
the liver to acetaldehyde through the action of the highly expressed enzymes
alcohol dehydrogenase (ADH) and Cytochrome P450 2E1 (CYP2E1).
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1.1.3 Acetaldehyde Metabolism
1.1.3.1 ALDHs as Mediators of Acetaldehyde Metabolism
Acetaldehyde, CH3CHO is a major substrate of ALDH2 and ALDH1B1
enzymes (Table 1.1, Figure 1.2). These isozymes are located in the
mitochondria and have a high affinity for aliphatic aldehydes including
acetaldehyde (Km = 0.2 µM, 55 µM) and propionaldehyde (Km = 0.095 µM, 14
µM) (Stewart et al., 1995; Stagos et al., 2010; Klyosov, 1996). The specificity
of these ALDHs toward their substrates is determined by the residues that line
the hydrophobic tunnel of each ALDH subunit (Koppaka et al., 2012). At the
base of this hydrophobic tunnel is the enzyme active site, which is positioned
opposite to the cofactor binding site. The base of the tunnel is located in
proximity to the linker region. This linker (or oligomerisation) region enables
dimerisation of each monomeric subunit. Two homodimers are consequently
assembled into the tetrameric (dimer of dimers), which is the catalytically
active form of the enzyme, containing four active sites, one per monomer
(Figure 1.1). Both ALDH1B1 and ALDH2 function as homotetrameric
enzymes (Rodriguez-Zavala and Weiner, 2002; Lutfullah et al., 2011). The
active site of acetaldehyde-metabolising ALDHs binds a single aldehyde
molecule and the cofactor nicotinamide adenine dinucleotide (NAD+) or
nicotinamide adenine dinucleotide phosphate (NADP+) in their oxidised
states. NAD+ is a cofactor for ALDH1B1 and ALDH2 enzymes whereas
NADP+ serve only as a cofactor for the ALDH1B1 isoform.
All of these functional regions; coenzyme binding domain, catalytic domain
and linker domain have a high degree of structural homology between ALDHs,
despite differences in their substrate preference. The capacity of ALDH1B1
and ALDH2 to catalyse oxidation is afforded by possession of the amino acid,
cysteine at position 302 (Cys302) (Figure 1.1). The Cys302 residue is
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completely conserved in all catalytically active members of the ALDH family
alongside asparagine at position 169 (Asn169) (Perozich et al., 2008; Hempel
et al., 1999). The Cys302 residue is critical for nucleophilic attack of
acetaldehyde, which is responsible for forming a covalent enzyme-substrate
intermediate. Performing classical site-directed mutagenesis experiments on
the ALDH active site residues enabled dissection of the functional amino acid
residues for activity. By mutating the cysteine amino acid residue to alanine
(C302A), a tetrameric enzyme was generated that maintained NAD+-binding
but lacked dehydrogenase and esterase activity (Farres et al., 1995).
Replacement of Cys302 for Ser302 (C302S) led to a reduction in the
enzymatic rate of ALDH2. This is because the hydroxyl group of serine is a
weaker nucleophile than the sulfanyl group of cysteine. This confirmed that
Cys302 was an essential amino acid for ALDH activity.
1.1.4 Aldehyde Detoxification
Short-chain aldehydes that include formaldehyde and acetaldehyde are DNA-
and protein-damaging agents which present a toxic metabolic challenge to the
cell that must be eliminated or repaired. Elimination of aldehydes occurs
through degradation or inactivation of aldehydes (Tier I protection),
predominantly by ALDH enzymes. Substrates of ALDH1B1 and ALDH2
enzymes that are directly relevant to this project are highlighted in Table 1.2.
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Table 1.2: Biological Aldehyde Substrates of ALDH1B1
and ALDH2
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Figure 1.1: Tetrameric Structure of ALDH2
Structure of the human mitochondrial aldehyde dehydrogenase
complexed with cofactor NAD+. Individual subunits are coloured
differently. Ribbon view and Gaussian surface representation to
show ALDH2 monomeric subunits. Gaussian surface
representation demonstrates the presence of the hydrophobic
tunnel in ALDH2 subunits and bound position of the cofactor.
Expanded ribbon view of the base of the hydrophobic tunnel of an
ALDH2 monomer highlights that the active site cysteine residue,
Cys302 (labelled CYS 302) is positioned opposite to the NAD+
cofactor binding domain. Bound NAD+ is highlighted on the ribbon
structure in purple. This figure was producted using the RSCB
Protein Databank (PDB) and crystal structure data from Larson
et al. (2007).
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1.1.4.1 Acetaldehyde Fate and Consequences of Acetaldehyde
Exposure
The major site of acetaldehyde detoxification is the liver. In cells with
competent acetaldehyde-metabolising ALDH enzymes, acetaldehyde is
detoxified by oxidation to acetic acid (Figure 1.2). Free acetic acid dissociates
at cellular pH 7.4 to acetate anions and protons. Acetate enters the
mitochondria where it undergoes rapid assimilation alongside coenzyme A
(CoA) into acetyl coenzyme A (acetyl-CoA) via ligation of acetyl-CoA and
acetate (Figure 1.3). The resulting acetyl-CoA is a key metabolic intermediate
that can be used for oxidation through the tricarboxylic acid cycle and is
central to many metabolic reactions (Shi and Tu, 2015; Pietrocola et al.,
2015).
Figure 1.2: Oxidation of Acetaldehyde by Aldehyde Dehydrogenase
Enzymes
ALDH isozymes ALDH1B1 and ALDH2 catalyse irreversible
oxidation of the acetaldehyde carbonyl to its respective carboxylic
acid, acetic acid. Oxidation of acetaldhyde is coupled to reduction
of the cofactor NAD+ (for ALDH2 and ALDH1B1) or NADP+ (for
ALDH1B1) and generates NADH or NADPH as a reaction product.
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1.1.5 Retinaldehyde Metabolism
1.1.5.1 ALDHs as Mediators of Retinaldehyde Metabolism
Retinaldehyde is a major substrate of ALDH1A1, ALDH1A2 and ALDH1A3
isozymes (RALDH1, RALDH2, RALDH3) (Yoshida et al., 1992).
Retinaldehyde is biosynthesised in the cell by the reversible action of retinol
dehydrogenases (RDH) on retinol (vitamin A). ALDH1A1, 1A2 (Zhao et al.,
1996; Wang et al., 1996) 1A3 and 8A1 enzymes catalyse the irreversible
cytosolic oxidation of retinaldehyde to retinoic acid (RA) (Figure 1.4).
Oxidation of retinaldehyde yields the retinoic acid (RA) isomers, all-trans-RA
(ATRA), 9-cis-RA and 13-cis-RA. ALDH1A1 has high affinity for all-trans- and
9-cis-retinal, whereas ALDH1A3 has a high affinity for all-trans-retinal (Table
1.1).
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Figure 1.4: Retinaldehyde Metabolic Pathway
Retinol is metabolised through retinol dehydrogenase (RDH)
enzymes to retinaldehyde. Retinaldehyde is oxidised to retinoic
acid by the action of the ALDH1 subfamily of ALDH enzymes.
All-trans-retinaldehyde has the lowest Km for the ALDH1A3
isoform.
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1.1.5.2 Downstream Effects of Retinoic Acid
Retinoic acid isomers differ in their biological potency; of all three isomers,
ATRA exerts the most potent and experimentally-defined cellular effects. RA
binds to two familes of receptors, nuclear retinoic acid receptors (RAR) and
retinod X receptors (RXR). Both of these classes have α, β, γ isoforms.
Binding of the heterodimerised forms of these receptors to the retinoic acid
response element (RARE) drives transcriptional activation and expression of
RA target genes. Retinoic acid signalling is key during times of enhanced
transcriptional activation and control, including embryonic development and
adult differentiation during tissue repair and thus tissue-specific expression
and activity of ALDH is essential for governing these processes (Duester
et al., 2003).
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1.2 ALDHs in Disease
1.2.1 Biological Reactivity of Aldehydes
The electrophilic nature of aldehydes contributes to their high degree of
reactivity with environmental and biological matter. This reactivity of
aldehydes is provided by their characteristic formyl functional group (CHO).
The carbonyl group provides aldehydes (R-CHO) with an electrophilic carbon
that reacts readily with nucleophilic sites in DNA and proteins, leading to
aldehyde adduct formation.
A notable DNA adduct arising from acetaldehyde exposure is
N2-ethylidene-2′-deoxyguanosine (N2-Et-dG). It is the most abundant DNA
adduct resulting from ethanol and acetaldehyde exposure that has been
discovered so far (Wang et al., 2006; Matsuda et al., 2007). Despite ethanol
exposure being a desirable candidate for the identification of biomarkers for
human cancer, liver disease and alcoholism, investigation of mutational
spectra of acetaldehyde exposure have lagged behind investigations of
similar xenobiotics such as aflatoxin B1, for which characteristic mutational
spectra have been elucidated (Chawanthayatham et al., 2017). Although
biomarker discovery for acetaldehyde-specific DNA and protein adducts is in
its infancy, there has been much research on more general adducts such as
those arising from ethanol treatment. These DNA and protein adducts arising
from aldehyde or ethanol exposure can be reversible and irreversible
(Sonohara et al., 2019) but ultimately, their detoxification through mechanisms
that remove acetaldehyde (tier I) and those that repair acetaldehyde-induced
damage (tier II) is essential for maintenance of cell homeostasis and viability.
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1.2.2 Acetaldehyde Metabolism Underpins Disease
Pathogenesis
Aldehyde metabolism underpins many complex disease pathologies and cell
signalling pathways. In the past, aldehyde metabolism by ALDH has been
noted for its contribution to alcohol toxicity and related disease (Ambroziak
and Pietruszko, 1993; Amir, 1978; Horton, 1970). More recently, the field of
aldehyde metabolism has been expanded to include increasingly complicated
metabolic networks including DNA demethylation, methylation cycles and one
carbon metabolism (Bae et al., 2017; Burgos-Barragan et al., 2017). This
recent research has mostly focused on the involvement of other short chain
aldehydes, including formaldehyde, in metabolic networks. Although similar
studies of acetaldehyde exist, isotopic labelling of acetaldehyde is rarely
employed (Shukla et al., 2007; Chen et al., 2018). Key recent studies of
aldehyde biology have demonstrated that expression of ALDH2 and
ALDH1B1 is protective against ethanol and acetaldehyde-induced DNA
damage (Amanuma et al., 2015; Garaycoechea et al., 2018), which is
particularly relevant for alcohol-induced cancers and liver disease (Müller
et al., 2016, 2018).
1.2.2.1 Human ALDH Polymorphisms Demonstrate the Necessity of
Aldehyde Metabolism
The most significant reporter of ALDH2 function exists in the genome of 8% of
the World’s population (Brooks et al., 2009). A single nucleotide
polymorphism (SNP) in the ALDH2 gene (ALDH2*2) is the most frequently
identified single nucleotide variant. The ALDH2*2 allele arises from a single
point mutation of guanine to adenine. This mutation gives rise to an amino
acid substitution at position 487 of the ALDH2 protein of glutamate to lysine
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(E487K, or E504K when including the mitochondrial targeting sequence) in
the ALDH2 monomer (Yoshida et al., 1984; Steinmetz et al., 1997) (Figure
1.5). The ALDH2*2 monomer exerts a dominant negative effect when present
in the ALDH2 tetramer. Incorporation of only one defective ALDH2*2 subunit
in the overall ALDH2 tetramer depletes the enzymatic activity of the ALDH2
enzyme by 52%, whereas homozygotes for ALDH2*2 have closer to 1 - 4% of
the wild-type ALDH2*1 activity (Weiner et al., 2001). This means that
heterozygosity for ALDH2*2 is enough to significantly hamper cellular
oxidation of acetaldehyde to acetate. Although the ALDH2*2 polymorphism is
the most common SNP, suggesting there is a possible evolutionary
advantage of possessing the mutated allele, the SNP has been linked to
various pathogeneses and has revealed fundamental consequences of
defective aldehyde detoxification. The most famous example of this is
demonstrated by ALDH2*2 carriers who have a heavy intolerance to ethanol
consumption. Deficiency of ALDH2 acetaldehyde-metabolising capacity
manifests with facial flushing, headaches, nausea, dizziness, and cardiac
palpitations following alcohol consumption. The inability of ALDH2*2
individuals to metabolise ethanol is thought to underpin the enhanced risk
ALDH2*2 carriers have of developing digestive tract cancers (Chang et al.,
2017; Matsumoto et al., 2016).
1.2.2.2 Mouse Models Used for the Study of Aldehyde Metabolism
Mouse genetic mutants harbouring Aldh2-deficiency have been heavily
utilised as models of ALDH2*2 genetics. Pathogenic effects of ALDH
mutations are not limited to oncogenesis and span many organ systems.
Exposure of Aldh2 wild-type status mice to acetaldehyde led to a
preconditioning, upregulation of ALDH2 and subsequent protection against
cardiac ischaemia-reperfusion injury. Conversely, the same treatment of
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Aldh2*2 mice, with diminished ALDH2 activity, abolished the cardioprotective
effects of acetaldehyde and ethanol (Ueta et al., 2018). In some cases,
defective acetaldehyde metabolism is advantageous: For instance, in
enhancing sensitivity to chemotherapy, where Aldh2*2 mice exhibit enhanced
reactive oxygen species (ROS) production in response to cisplatin (Kim et al.,
2017).
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Figure 1.5: Possession of the ALDH2*2 Variant Disrupts ALDH2 Tetramer
Activity
The ALDH2*2 allele results from a single point substitution of
guanine to adenine and a substitution in the amino acid sequence
from glutamate to lysine which disrupts the dimerisation domain of
ALDH2 and prevents proper assembly of the ALDH2 tetramer.
ALDH2*2 monomers exhibit a dominant negative effect on ALDH
activity and prevent the oxidation of acetaldehyde to acetic acid.
Image based on figure from Gross et al. (2015).
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1.2.3 ALDHs as Markers of Tumour-Initiating Cells
1.2.3.1 Basis of the ALDEFLUOR™ Assay
ALDH enzymes are widely used experimental markers of tumour-initiating
cells. The ALDEFLUOR™ assay has been instrumental in the use of ALDH
as a marker of bonafide stem cells and tumour-initiating cells and its
usefulness was first demonstrated through isolation of ALDH-expressing
haematopoietic stem cells (Storms et al., 1999). The assay relies upon
metabolism of the fluorescent ALDEFLUOR™ reagent,
BODIPY-aminoacetaldehyde (BAAA) to a negatively charged and
membrane-impermeable BODIPY-aminoacetate conjugate (Figure 1.5). This
causes the metabolised reagent to accumulate within the cytosol and
generate a fluorescent signal that can be used to analyse and isolate cell
populations with flow cytometry. The ALDH inhibitor
4-(Diethylamino)benzaldehyde (DEAB) is used as a negative control in the
ALDEFLUOR™ assay. Although the mechanism of ALDH inhibition has not
been established for this compound, the low rate of turnover of the DEAB
benzyl aldehyde group to benzoate means that it essentially functions as a
competitive inhibitor (Morgan et al., 2015).
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Figure 1.6: ALDEFLUOR™ Assay for Monitoring Cellular ALDH Activity
Cells uptake the fluorescent BODIPY-aminoacetaldehyde
substrate. In cells that express ALDH isoforms which are capable
of BODIPY aminoacetaldehyde (BAAA) metabolism,
BODIPY-AAA is converted to the negatively charged BODIPY
aminoacetacetate. This conjugate is membrane impermeable and
therefore is retained in the cells which express ALDH, generating
a fluorescent read-out of ALDH activity.
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1.2.3.2 Tumour-Initiating Cells
Tumour-initiating cells were first described in leukaemia (Lapidot et al., 1994).
Given the lineage-orientated nature of the haematopoietic system,
extrapolation from this established developmental model gave rise to the
hierarchical model of tumour initiation and development. This model proposes
that tumours harbour a subpopulation of cells which are capable of
self-renewal and differentiation and that these cells are responsible for tumour
initiation and progression. This cancer subpopulation is thought to be
resistant to conventional chemotherapies, as a result of upregulated
drug-resistance genes or lower levels of cellular proliferation. ALDH was first
identified as a marker of a subpopulation of tumour-initiating cells in breast
cancer and leukaemia and since has been vastly used as a marker to
delineate tumour populations that coincide with drug resistance (Ginestier
et al., 2007; Cheung et al., 2007).
1.2.3.3 ALDEFLUOR™ as a Reporter of ALDH Activity in Tumour
Initiating Cells
Although ALDH1A1, ALDH1A2, ALDH1A3 and ALDH2 activity have been
shown to underlie ALDEFLUOR™-induced fluorescence in stem cells and
tumour-initiating cells, the contribution of individual ALDH isoforms to turnover
of ALDEFLUOR™ BAAA reagent in cells is unknown. The substrate
specificity of each ALDH isoform toward BAAA has not been reported but a
recent overexpression screen of the 19 human ALDH isoforms in kidney and
breast cancer immortalised cell lines alongside respective catalytic mutants
reinforced the notion of tissue-specific ALDEFLUOR™ activity, describing
nine isoforms which underlie BAAA turnover in these cell types (Zhou et al.,
2019).
22 Chapter 1
Aldehydes, gene-drug interactions and cancer subpopulations
1.2.4 ALDH in Melanoma
The functional importance of expression of ALDH1 enzymes in
chemoresistance is attributed to their role in retinoic acid synthesis. Retinoic
acid synthetic pathways have been widely explored as opportunities for the
modulation of drug tolerance. Retinoic acid has been used as a treatment
strategy to enhance the anticancer effects of many drugs but the mechanism
of how retinoic acid induces these effects is not understood.
Although exact models of cancer cell dynamics and tumour evolution are
subject of dispute, enrichment of ALDH enzymes at tumour sites during
radiotherapy and chemotherapy has been reported and targeting these
cellular subpopulations can overcome drug resistance (Duan et al., 2016).
Recently, Sarvi et al. (2018) and Pérez-Alea et al. (2017) independently
demonstrated that ALDH1A3 is upregulated in melanoma subpopulations and
that these populations are sensitive to the ALDH inhibitors, nifuroxazide and
dimethylthioampal (DIMATE). Pérez-Alea et al. (2017) attributed cytotoxicity
of DIMATE in ALDH1 populations to elevations in ROS and subsequent
generation of peroxidation markers, 4-Hydroxynonenal (4-HNE) and
Malondialdehyde (MDA). Sarvi et al. (2018) propose a two-hit mechanism of
nifuroxazide toxicity, the first through bioactivation of nifuroxazide to ROS and
the second through direct inhibition of ALDH1A3. Neither study addressed the
potential for accumulation of aldehydes and dysfunctional retinoic acid
signalling in the cytotoxic effects resulting from ALDH1A3 inhibition.
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1.2.5 Modifiers of ALDH Function
Given that isoforms in the ALDH family are important for detoxification or
generation of biologically important molecules and are upregulated or
dysfunctional in disease, they are attractive targets for the development of
ALDH isozyme-selective inhibitors and activators (Koppaka et al., 2012). The
natural product, Daidzin has antidipsotropic effects and is a selective,
reversible inhibitor that is specific to the ALDH2 isoform (IC50, 80 nM). Daidzin
inhibits ALDH function through binding to a hydrophobic cleft of the ALDH2
active site (Lowe et al., 2008). Inhibition of the ALDH2 enzyme is responsible
for the antidipsotropic effects of Daidzin.
Disulfiram (tetraethylthioperoxydicarbonic diamide) is used clinically for the
treatment of alcoholism, with effects upon alcohol consumption that mimic
possession of the ALDH2*2 polymorphism. Disulfiram is an irreversible,
non-selective inhibitor of ALDH isoforms (Lipsky et al., 2001). Disulfiram is
also a non-nucleoside DNA methyltransferase inhibitor (Lin et al., 2011). Due
to its dual pharmacological effects on both ALDH and DNA methylation, the
anticancer properties of Disulfiram have been widely studied (Yang et al.,
2019). Disulfiram is metabolised by hepatic thiol methyltransferases to
various metabolites that have the potential to carbamoylate and therefore
inactivate Cys302 of the ALDH2 active site (Koppaka et al., 2012).
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1.3 5-Nitrofurans
5-Nitrofuran compounds (5-NFNs) are a class of effective antiparasitic and
antibiotic drugs used in human and veterinary medicine. The clinical
application of 5-NFNs is broadening; some 5-NFNs have emerged as
potential chemotherapeutic agents. Nifurtimox (NFX) has been repurposed in
clinical trial for neuroblastoma and neuroblatoma therapy (Saulnier Sholler
et al., 2006, 2009, 2011a,b). Recently, nifuroxazide has been shown in
principle to provide effective therapy against minimal residual disease in
melanoma (Sarvi et al., 2018).
1.3.0.1 Clinical Use of Nifurtimox in Chagas Disease
Nifurtimox is used for the treatment of human American trypanosomiasis
(Chagas disease), as a second line option to benznidazole and as a
combination therapy with eflornithine for second-stage human African
trypanosomiasis (sleeping sickness). The causative agents of these diseases,
Trypanosoma cruzi (T. cruzi) and Trypanosoma brucei (T. brucei) are present
in millions of people worldwide; the most recent estimates for T. cruzi
infection range between six and ten million people (Bonney, 2014; WHO,
2017). Twenty-five million people are at risk of Chagas disease (WHO, 2012),
the disease is endemic in Latin America and migration has led to increased
incidence of infection in non-endemic regions such as North America, Europe,
Australia and Japan (Gascon et al., 2010). Untreated Chagas disease often
results in life-long morbidity and disability which severely reduces quality of
life for patients. This combined mortality and disabling effects of Chagas
disease and their treatment means that they are a primary target for the World
Health Organisation (WHO). Nifurtimox, is one of only two drugs used to treat
Chagas disease and one of three used to treat second stage sleeping
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sickness. Nifurtimox is of such importance in tackling the burden of Chagas
disease that the WHO has classified it as an essential medicine (WHO, 2017).
1.3.1 Antiparasitic and Antibiotic Mechanisms of
5-Nitrofurans
Despite the use of nifurtimox against Chagas disease spanning 40 years, the
mechanism of action of nifurtimox has not been elucidated in its entirety.
Various mechanisms of action have been proposed, including oxidative stress
induction, nitroreductase-mediated bioactivation and roles of the
prostaglandin F2 synthase and cytochrome P450 reductase enzymes (Hall
et al., 2011).
1.3.1.1 Nitroreductase Enzymes
As with all prodrugs, 5-NFNs require metabolism to generate
pharmacologically active derivatives. Bioactivation of 5-NFNs occurs via two
sequential nitroreduction reactions that yield an active hydroxylamine
derivative. Reduction of the nitrofuran functional group, 5-NO2-furan (Figure
1.7) is catalysed by nitroreductase enzymes (NTRs) and leads to generation
of ROS and cell death induction (Maya et al. (2007)). The nitroreductases
(NTRs) responsible for reduction of nifurtimox are commonly found in bacteria
and protozoa, but are sparse in higher eukarotes. This is ideal from a drug
selectivity perspective, in that nifurtimox can efficiently kill bacteria and
parasites without bioactivation by potential host NTRs at sites other than the
prokaryote.
In an effort to determine the selectivity of nifurtimox against T. brucei, Hall
et al. (2011) overexpressed multiple enzymes thought to metabolise nifurtimox
in T. brucei and monitored susceptibility to nifurtimox under these conditions.
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Increasing expression levels of eukaryotic type I nitroreductase alone was
enough to alter sensitivity to the drug and so NTRs were implicated with a key
role in the anti-trypanosomal activity of nifurtimox (Figure 1.8). Furthermore,
loss of a single copy of type I NTR in T. cruzi by targeted gene deletion
causes cross-resistance to nitroheterocyclic drugs, including nifurtimox,
without affecting the infectivity of the parasite (Wilkinson et al., 2008).
Figure 1.7: 5-Nitrofuran Compounds
5-Nitrofurans with bioactivated groups indicated in red. The
5-nitrofuran functional group, 5-NO2-furan is reduced by
prokaryotic nitroreductase enzymes and undergoes bioactivation
in zebrafish by ALDH2b. NFN1, nitrofuran-1; NAZ, nifuroxazide;
NFX, nifurtimox.
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Figure 1.8: Type I Nitroreductase Enzymes Catalyse Reduction of
5-Nitrofurans
Type II Nitroreductases initially reduce 5-nitrofurans to a 5-NFN
radical. Type I Nitroreductases catalyse reduction of the
5-NO2-furan functional group. Nitroreduction generates a nitroso
intermediate and subsequently a hydroxylamine. The
hydroxylamine derivative is metabolised to form the nitrenium ion,
the amine form, or unsaturated and then saturated open-chain
nitriles. 5-NFN radicals can also reduce oxygen to a radical
species which undergoes redox cycling with super oxide
dismutase, promoting additional ROS formation. Figure from Hall
et al. (2011).
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1.3.2 5-Nitrofuran Off-Target Effects
Despite bioactivation of nifurtimox occuring through the action of bacterial and
parasite-specific NTRs, nifurtimox causes complex adverse effects. These
effects progressively worsen during the treatment course of 8-10 mg/kg for
60-90 days. The side effects of Chagas treatment with nifurtimox are often
more considerable than the symptoms of Chagas disease, which manifest
during the acute stage as mainly flu-like or asymptomatic (Gascon et al.,
2010; WHO, 2011, 2012).
The most common nifurtimox symptoms are anorexia and weight loss,
dizziness, psychic alteration, sleepiness and digestive problems including
nausea, vomiting, intestinal colic and diarrhoea as well as neurological
symptoms including polyneuropathy (Castro et al., 2006). These serious side
effects lead to treatment cessation in a third of patients with Chagas (Castro
et al., 2006). Side effects of nifurtimox can vary between populations but
interestingly, these side effects are exacerbated when patients consume
alcohol alongside their treatment and patients become intolerant to alcohol.
This provides an intriguing hypothesis that alcohol and nifurtimox share a
common molecular target.
Considering this, there is a clear, unmet need for development of a
treatment strategy or refinement of therapeutic guidelines to reduce the
off-target, toxic side effects of 5-NFNs. This is important not only for treatment
of individual cases but to control the endemicity of Chagas disease, that like
most other zoonoses, will never be fully eradicated (WHO, 2017). As of yet,
such remedial treatments or drugs with lower toxicity but the same
anti-trypanosomal effects have not been identified. Consequently, to refine
current approaches of nifurtimox therapy and reduce the off-target side effects
of 5-NFNs, understanding the mechanistic underpinnings of side effect
development is essential.
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1.4 Mechanisms of 5-Nitrofuran Toxicity
Multiple human enzymes capable of 5-nitrofuran reduction have been
identified and are predominantly NAD(P)H quinone oxidoreductases (Morgan
et al., 2015). However, whether these enzymes are relevant to 5-nitrofuran
side-effects and have potential for therapeutic intervention to inhibit the
off-target effects of 5-nitrofurans in vivo is unanswered. ALDH enzymes are a
candidate target for the mediation of 5-nitrofuran adverse effects. Zebrafish
ALDH2b was discovered as a target of 5-NFNs and bioactivation of NFN1 in
zebrafish induced melanocytotoxic effects (Zhou et al., 2012). 5-nitrofurans
are widely documented to cause DNA damage and yeast strains harbouring
deletions in DNA damage repair pathways causes hypersensitivity to
5-nitrofurans (Zhou et al., 2012). The underlying DNA damaging agent(s) for
this response remains to be established. A methodological means to evaluate
the potential generation of DNA-damaging ALDH substrates that might
underlie this interaction would support these studies.
1.5 Approaches to Quantify Aldehydes In Vivo
Given ever-increasing recognition of aldehydes as key cellular signalling
molecules, there is a current unmet need for markers of
acetaldehyde-induced damage as well as methods to quantify levels of
circulating aldehydes.
1.5.1 Methods of Aldehyde Detection
Aldehydes are volatile and polar compounds that are susceptible to
biochemical degradation (Table 1.3). These properties make them a
problematic class of compounds to reliably quantify, particularly in biological
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contexts. Large-scale detection of aldehydes and carbonyl groups in general
is routinely performed in environmental chemistry. Aldehydes have a critical
impact on the environment and contribute to pollution, ozone formation and
photochemical smog, thus their detection in air, water and soil matrices is
essential for measurement and control of air pollution. Even on large scales,
such as when determining aldehyde content in ambient air, the reliability and
robustness of these measurements are contentious (Herrington et al., 2007).
Despite increasing recognition of aldehydes as fundamental biological
molecules, there is a need for methods that accurately quantify aldehydes in
biological fluids. The volatile nature of aldehydes and their capacity to
degrade to carboxylic acids, causes acetaldehyde quantification in biological
tissues to be a challenge. When applying large scale reactions such as those
used in environmental chemistry to small scales such as quantifying relatively
small differences in biological fluids that may be sufficient to have
physiological implications but are under the detection threshold of current
analytical methods, reactions can not be simply scaled down to the amount of
compound being analysed. As a consequence, the lack of efficient means to
quantify and trace aldehydes in biological systems means that understanding
aldehydes as signalling and DNA-damaging molecules both in vitro and in
vivo is hindered.
Aldehydes can be detected in biological samples including blood plasma
and urine. Gas and liquid chromatography combined with mass spectrometry
are the most common methods used for aldehyde analysis in these matrices,
although enzyme-based assays are also used.
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Linear Formula HCHO CH3CHO CH3CH2CHO
Molecular Weight 30.026 44.053 58.079
Monoisotopic Mass 30.026 44.026 58.042
Boiling Point -19.5 20.2 48.8
Density 0.815 0.785 0.805
Molecular weight and monoisotopic mass reported in g/mol, boiling point reported
in °C, density reported at 25°C in g/mL.
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1.5.1.1 Enzyme Assays for Aldehyde Quantification
Colorimetric assays are used for the quantification of acetaldehyde in
biological samples (Sung et al., 2012; Abraham et al., 2011; Müller et al.,
2016; Zhang et al., 2018). These assays utilise the following reaction:
CH3CHO + NAD+ + H2O ALDH−−−→ CH3COOH + NADH + H+
Acetaldehyde quantification with this method is based on oxidation of
acetaldehyde that is catalysed by ALDH. NADH generated during the reaction
reduces a formazan reagent and the product, which is proportional to the
acetaldehyde concentation, is measured with UV-Vis spectrometry at 565 nm.
The linear detection range for 10 µL of sample with this assay is reportedly
4 µM to 4 mM. As this assay relies on ALDH to quantify acetaldehyde, the
enzyme also oxidises other aldehydes present in the sample, including
propionaldehyde. This means that acetaldehyde is not distinguished from
other aldehyde substrates of the recombinant ALDH. In many of the reported
experiments that use this technique, ethanol is the major metabolic precursor
administered and so it is reasonable to assume that the majority of aldehyde
load detected is acetaldehyde. Additionally, enzymatic assays for the
measurement of acetaldehyde are susceptible to inaccuracies due to the
volatility of acetaldehyde as both a prepared standard for standard curve
generation, and as a sample analyte in cell or plasma matrices. Enzymatic
assays are performed at 25°C and so losses of acetaldehyde during sample
collection and throughout the timecourse of the experiment is inevitable.
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1.5.1.2 Chromatographic and Mass Spectrometric Assays for Aldehyde
Quantification
1.5.1.3 Derivatisation of Aldehydes
The volatility and low response of aldehydes in liquid chromatography-mass
spectrometry (LC-MS) presents analytical challenges. For analysis of highly
polar aldehydes, derivatisation is a method that can be used to improve
detection and quantitation in both gas chromatography-MS and LC-MS.
Derivatisation involves the reaction of an analyte (aldehyde in this instance)
with a reactive compound to yield a product that should be more amenable to
analysis. Analyte derivatisation has many desirable effects on analyte
characteristics, which improve the detectability and enhance chromatographic
and fragmentation properties of analytes (Eggink et al., 2010):
• increase the stability of the analyte
• improve the separation from matrix components in sample pre-treatment
and/or chromatography
• enhance the ionisation efficiency
• alter the fragmentation characteristics in MS
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1.5.1.4 Agents for Carbonyl Derivatisation
Carbonyl groups of aldehydes can be readily derivatised using
2,4-dinitrophenylhydrazine (DNPH) (Figure 1.9). By derivatising aldehydes
with DNPH to their corresponding aldehyde 2,4-dinitrophenylhydrazones,
indirect detection of aldehydes is facilitated (Figure 1.10). The derivatisation
reaction is relatively quick and simple and the resulting stable aldehyde
2,4-dinitrophenylhydrazone can be subjected to chromatographic and
mass-spectromic analyses for sample detection and analysis. Derivatisation
reagents contain a reactive functional group that selectively reacts with a
complementary functional group in the analyte (Eggink et al., 2010). In this
case, DNPH reacts with carbonyl groups of aldehydes. The advantage of this
reactivity, afforded by the carbonyl functional group, is that it allows detection
of multiple aldehydes in a complex mixture simultaneously. Despite
possessing the same functional group, different aldehydes can be detected
simultaneously because each aldehyde 2,4-dinitrophenylhydrazone exhibits a
distinct molecular weight that will alter the retention time on the column
material during HPLC separation and as DNPH has a molecular weight above
the 50 Da detection limit of high-resolution accurate-mass mass
spectrometers, all derivatised aldehydes should be detectable. Notably, in
addition to raising the molecular weight of aldehydes, the reaction has the
added benefit of reducing aldehyde volatility, preventing loss of aldehyde from
the sample (Table 1.4).
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Figure 1.9: Generic Derivatisation Reaction of DNPH with Aldehyde
DNPH reacts readily with carbonyl groups in aldehydes to
generate hydrazone derivatives that have increased stability, are
ionised more efficiently and have altered fragmentation
characteristics making the compounds more amenable to analysis
than non-derivatised aldehydes.
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Table 1.4: Effect of Aldehyde Derivatisation on the Molecular Weight and
Volatility of Aldehydes




derivatised formaldehyde-2,4-DNPH 210.2 357.8
derivatised acetaldehyde-2,4-DNPH 224.2 382.5
derivatised propionaldehyde-2,4-DNPH 238.2 391.7
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1.6 Thesis Outline and Aims
There is ever-increasing evidence to show that ALDH enzymes are important
in physiology and pathophysiology, especially as markers of cell populations.
The importance and role of the major ALDH substrates and ALDH reaction
products in relaying these biological effects is less understood. Understanding
ALDH as a target of 5-nitrofuran prodrugs has relevance to current treatment
strategies and the imminent application of nitrofurans as anticancer agents.
This thesis comprises three key research aims that span three chapters. Aims
are as follows:
1. Understand whether the ALDH:5-NFN enzyme-drug interaction is
relevant in mammalian systems and downstream effects of the
interaction, focusing on the liver as the main site of nitrofuran
metabolism and acetaldehyde detoxification.
2. Develop an aldehyde derivatisation approach suitable for
LC-MS-detection to enable detection of multiple aldehydes in blood
plasma.
3. Investigate transcriptional differences in ALDHhigh, ALDHlow and
ALDHnull populations in melanoma to determine whether
ALDH1A3-expressing cells exhibit a differential gene expression that




This chapter describes the general methods, reagents and instruments used to
perform experiments performed in this thesis. Experimental methods relating
to chromatographic and mass spectrometry analyses are detailed in Chapter
4.
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2.1 Cell and Tissue Culture
2.1.1 Cell Line Maintenance and Culture Conditions
All cell culture work was performed in a laminar flow hood under aseptic
conditions. Human hepatoma (HepG2) and human melanoma (A375) cell
lines (Figure 2.1) were obtained from ECACC collections (ECACC 85011430,
ECACC 88113005). All cell line experiments were performed on cells at
passage 5 to 15. Cell lines were screened every three months for
mycoplasma contamination. Cells were grown to confluence in growth
medium; DMEM; L-Glutamine, 2 mM ; FBS, 10% (v/v ). Cells were incubated
at 37°C in a 5% CO2 humidified atmosphere (Heraeus HERAcell 51013669
CO2 incubator). Cell monolayers during growth phase or at 80% confluency
were washed with phosphate buffered saline (PBS) and cells detached using
0.5% or 0.25% Trypsin-EDTA for A375 and HepG2 cells, respectively.
Following detachment, trypsin was inactivated by addition of growth medium
and cells were pelleted in 30 mL conical tubes by centrifugation at 1000 rpm
for 5 min with a Eppendorf™ 5810 R centrifuge. Following pelleting, cells
were gently resuspended in growth medium by pipetting. To minimise HepG2
cell clumping, cell suspension was passed through a 25 gauge needle
attached to a 10 mL syringe. Cells were re-plated at split ratios appropriate to
each cell line, 1:4 (HepG2) and 1:6 (A375) or were seeded into plate wells for
experimental analysis.
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For cryopreservation, cells in growth phase were trypsinised and pelleted
as above and the resulting cell pellet cryopreserved in freezing medium;
Ham’s F-10 48% (v/v ); tryptose phosphate broth (TPB), 40% (v/v ); DMSO,
12% (v/v ). Cryotubes were placed in Mr. Frosty™ freezing containers that
were pre-equilibrated to -80°C before long-term cryostorage. For cell
recovery, cryotube contents were rapidly thawed by immersion in a water bath
at 37°C. Cells were resuspended in 10 mL pre-warmed growth medium and
centrifuged at 1000 rpm before resuspension of the pellet and plating in fresh
media. Cells were passaged at least three times after recovery before
experimentation.
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Figure 2.1: Cell Line Morphology
Human hepatoma (HepG2) and human melanoma (A375) cell
lines obtained from ECACC collections (ECACC 85011430,
ECACC 88113005).
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2.2 Cell Viability and Cytotoxicity
2.2.1 Growth Curves
To identify the optimal number of cells to plate for analysis of cell growth in
the presence of small molecules and aldehydes, growth curve analysis was
performed over seven days. Cells were resuspended in fresh growth medium
and seeded in 96-well plates in a half-log dilution series ranging from 100,000
cells/well to 0 cells/well in 100 µL of media. Following incubation at 37°C and
5% CO2 in a humidified atmosphere, cell growth was analysed every 24 h by
PrestoBlue® assay.
2.2.2 Cell Viability and Cytotoxicity
Following trypsinisation, cells were resuspended in fresh growth medium and
1000 cells were plated/well of 96-well cell culture plates. Following overnight
incubation, media was aspirated and 100 µL of fresh growth media containing
half-log serial dilutions of desired compound (10 µM – 1 nM) or DMSO control
(0.1%) was pipetted into each well via multichannel pipette. Cells were
incubated at 37°C and 5% CO2 in a humidified atmosphere for the treatment
exposure period.
For acetaldehyde and NFN1 treatment of HepG2 cells, after overnight
incubation of seeded cells, fresh growth media was supplemented with
acetaldehyde at 10 mM, 5 mM, 2.5 mM and 0 mM concentrations and 95
µL/well supplemented growth media was added to the wells of each plate,
with one plate per acetaldehyde condition. Five microliters of DMSO control
or desired compound (NFN1) was added in half-log dilution series to the wells
of each plate. Nitrofuran and acetaldehyde conditions were replenished daily
by removal of media and addition of freshly-prepared NFN1, acetaldehyde
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and DMSO control to cells. Cells were incubated at 37°C and 5% CO2 in a
humidified atmosphere for the treatment exposure period.
2.2.3 PrestoBlue® Assay
PrestoBlue® is a resazurin-based cell permeable redox indicator that is
reduced in living cells to indicate viability. In living cells, PrestoBlue® is
converted from its oxidised state (resazurin, blue) to its reduced form
(resorufin, red). The reduced form absorbs at 570 nm and is highly
fluorescent (λex 535 nm, λem 612 nm). PrestoBlue® reagent, 10 µL was added
to 100 µL of media in each well of the 96-well plate containing cells or blank
wells. Cells were incubated with reagent for 30 min at 37°C and 5% CO2
humidified atmosphere before measuring fluorescence (λex 535 nm, λem 612
nm) using the automated 96-well plate reader Infinite® M200 PRO (Tecan,
Switzerland) (Table 2.5).
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Table 2.5: Fluorometer Settings for Analysis of the PrestoBlue
Assay
Measurement Parameter Infinite® M200 Pro Settings
Plates Corning™ Costar™ 96 Flat Bottom




Mode Top (T) / Bottom (B)
z-position (top fluorescence) calculated from sample well
Excitation wavelength (λex) 560 nm
Emission wavelength (λem) 600 nm
Gain Optimal
Number of flashes 25
Settle time 0 ms
Lag time 0 µs
Integration time 20 µs
Reads per well 1
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2.2.4 PrestoBlue® Quantification
All plate readings were performed using the Infinite® M200 PRO (Tecan,
Switzerland). Data was exported with Magellan™ software (Tecan,
Switzerland) and analysed in Prism 7 (GraphPad). The average value for
each sample was calculated and corrected by subtracting the average blank.
Fluorescence values (PrestoBlue®) were plotted against cell number to
visualise cell growth curves. For cell viability curves, concentration of drug
was plotted against fluorescence values and sigmoidal dose curves generated
using Prism 7 (GraphPad). The average for each dilution was calculated (from
six wells) and corrected by subtracting the average blank. This value was
then related to the average of untreated control samples and the respective
error bars were calculated. The mean half-maximal effective concentration
(EC50) was used as an indicator of cytotoxicity to compare treatment
conditions. Values represent the average mean of at least 3 experimental
repeats and error bars represent the standard error of the mean (SEM).
2.2.5 Synergy vs Antagonism Modelling
To quantify synergistic or antagonistic effects of compound exposure,
model-based quantification of drug combinations was performed with
Combenefit (v2.02) (Di Veroli et al., 2016). Fluorescent intensity from
PrestoBlue®-turnover was normalised to percentage cell viability, with DMSO
control deemed to confer 100% cell viability. Dose-response (%) matrices for
NFN1 and acetaldehyde single and combined exposure were generated and
visualised with surface modelling. Synergy matrices were generated using the
three most common models; highest single agent (HSA) model, Loewe
additivity model and Bliss independence model. BLISS, HSA and LOEWE
models were mapped to dose-response for graphical visualisation.
51 Chapter 2
Aldehydes, gene-drug interactions and cancer subpopulations
Table 2.6: Cell Viability and Cytotoxicity
Reagent Supplier Cat No
PrestoBlue™Cell Viability Reagent Invitrogen A13262
Invitrogen™Trypan blue stain (0.4%) Fisher Scientific 10702404
Table 2.7: Reagents For Cell Treatments
Reagent Supplier Cat No
5-Nitrofurans
Nifurtimox ≥98% Sigma-Aldrich N3415
Nifuroxazide ≥97% EMD Millipore 481984
NFN1 Maybridge BTB05727SC
Aldehyde
Supelco™ Acetaldehyde ≥99.0% Sigma-Aldrich 00071
Vehicle
Dimethyl sulfoxide (DMSO) ≥ 99.7% Sigma-Aldrich D2650
52 Chapter 2
Aldehydes, gene-drug interactions and cancer subpopulations
2.3 Precision-Cut Liver Slices
2.3.1 PCLS Preparation
2.3.1.1 Liver Dissection
Six-to-eight week C57BL/6 mice were euthanised through CO2 inhalation and
livers were harvested rapidly to prevent ischaemic damage. Livers were
perfused by administration of ice-cold PBS through the inferior vena cava and
were dissected using scissors and forceps. Livers were stored on ice in HBSS
before transfer to a cell culture dish containing ice-cold HBSS. Liver lobes
were separated into lobular structures (Figure 2.2) using a single-edged blade
and forceps.
Figure 2.2: Annotation of Liver Lobes Used for Preparation of PCLS
Liver tissue samples were prepared from the left lateral lobe
(yellow dashed line) of 6-8 week C57BL/6 mice.
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2.3.1.2 Liver Coring
A single liver lobe was transferred onto a dissection/coring board wetted with
HBSS. The liver was cut into square fragments, maintaining the thicker, more
central parts of the liver lobe that yield more intact, round liver slices.
Fragmented liver tissue was placed under the tissue coring press
(MD2000/2300, Alabama Research and Development) and as many
cylindrical cores were obtained from large lobes as possible (≈ 2 cores) and
small lobes (≈ 1 core). After each liver lobe was cored, cores were
transferred using a stainless steel spatula to cell culture dishes containing
ice-cold HBSS for a maximum of 20 min.
2.3.1.3 Liver Sectioning
The Krumdieck tissue slicer (TSE Systems) reservoir was filled with HBSS
and the whole unit was pre-chilled in a cold room. Liver cores were
individually transferred to the cylindrical core holder of the Krumdieck slicer
and sectioned into PCLS of 200 µM thickness. Slices were transferred to a 2 L
glass beaker by flushing through the system after the slicing of each individual
core. After each core was sectioned and whilst the following core was being
sectioned, liver slices were transferred with a stainless steel spatula to
pre-warmed and oxygenated 24-well plates labelled with the type of lobe and
sequential number of each section. Each well contained 1 mL supplemented
DMEM; GlutaMAX™, 1X; FBS, 10% (v/v ); penicillin-streptomycin 1% (v/v ).
Slices were pre-incubated for 3 h at 37°C, 5% CO2 to increase viability of
sections. Livers from 8-10 week mouse primary liver lobes generated enough
material to prepare 20 slices. It has been previously reported that each liver
slice remains viable for up to 96 h (de Graaf et al., 2010).
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2.3.2 PCLS Drug Treatment
After pre-incubation, sections were transferred into 6 well plates containing 3
mL of supplemented DMEM; 1X GlutaMAX™; FBS 10%(v/v );
penicillin-streptomycin 1% (v/v ), containing the appropriate concentration of
NFN1. Serial dilutions of NFN1 in media were prepared to give
concentrations ranging from 0 µM - 10 µM (0.1% DMSO). Dilutions prepared
in falcon tubes and then transferred to wells of 6-well plates. Liver sections
were incubated for 20 h at 37°C in NFN1 or control vehicle (0.1% DMSO)
before protein extraction and ALDH activity analysis.
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2.4 Protein Extraction and Analysis
2.4.1 Protein Extraction and Quantification
2.4.1.1 Cell Lysate
To prepare cell lysates, growth media was removed from cells and cells were
washed with ice-cold PBS. RIPA buffer, 50 - 500 µL containing protease and
phosphatase inhibitors was added directly to the flask surface to lyse the cell
monolayer. Plates or flasks were then incubated on ice for 30 min to promote
cell lysis before scraping of lysate into pre-chilled 1.5 mL Eppendorf® tubes.
Cell lysates were centrifuged at 13000 rpm for 2 min and the supernatant
recovered into fresh 1.5 mL tubes. Cell lysates were either used immediately
in downstream analyses or were snap-frozen using liquid nitrogen and stored
at -80°C.
2.4.1.2 Tissue Lysate
For the preparation of PCLS lysates, growth media was removed from slices
and slices were washed twice with ice-cold PBS. Each slice was transferred
to a 2 mL microcentrifuge tube on ice and weighed before addition of 1 mL
of ice-cold tissue homogenisation solution (100 mM Tris-HCl, 2 mM EDTA, pH
7.6) supplemented with protease and phosphatase inhibitor tablets. Tissues
were homogenised using a single 3 mm Tungsten Carbide Bead per tube and
a pre-cooled TissueLyser LT (Qiagen) for 6 min at a speed of 50 Hz (3000
oscillations/min). Tissue lysates were spun at 12000 rpm for 10 min before
supernatant was removed and stored on ice ready for analysis. ALDH activity
was measured immediately after harvesting of tissues, or supernatants were
snap-frozen on liquid nitrogen and stored at -80°C before western blotting.
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2.4.1.3 Protein Quantification
Protein concentration of cell and tissue lysate was determined using
bicinchoninic acid (BCA) in 96-well plate format according to manufacturer
protocol. Protein standards were generated by dilution of 2 mg/mL BSA in
RIPA lysis buffer to yield 2000, 1500, 1000, 750, 500, 250, 125, 25, 0 µg/mL
BSA standards. BCA working reagent was prepared in 50 mL conical tube
with 50 mL of BCA reagent A added to 1 mL reagent B. If samples contained
high protein concentrations, a small volume of sample was diluted in RIPA
buffer prior to analysis. Twenty-five microliters of each standard or unknown
sample was pipetted into the wells of a 96-well plate in triplicate. Two-hundred
microlitres of working reagent was added to each well and the plate incubated
at 37°C for 30 min. Optical density (OD) was measured using the automated
96-well plate reader Infinite® M200 PRO (Tecan, Switzerland) at a wavelength
of 562 nm. OD values were converted to protein concentration through BSA
standard curve interpolation using Prism 7 (GraphPad). If samples were
pre-diluted, the protein concentrations were adjusted by the dilution factor.
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Table 2.8: Protein Extraction and Quantification
Reagent Supplier Cat No
RIPA Buffer SLS Sigma-R0278
cOmplete™ ULTRA Protease Inhibitor Roche 5892970001
PhosSTOP™ Roche 4906845001
Cell Scraper, 28 cm Greiner Bio-One 541070
Gibco™ HEPES (1M) Thermo Fisher 15630080
Tungsten Carbide Beads, 3 mm QIAGEN 69997
Pierce™ BCA Protein Assay Kit Thermo Scientific 23225
Corning™ Costar™ 96-well plate Fisher Scientific 10695951
Pierce™ Bovine Serum Albumin Thermo Scientific 23210
Microcentrifuge Tubes, 2 mL Thermo Scientific 11838332
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2.4.2 Protein Separation and Western Blotting
Twenty micrograms of protein per sample was added to sample buffer;
sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE)
sample loading buffer (6X) with 2-mercaptoethanol. Samples were totalled to
a volume of 40 µL per well with radioimmunoprecipitation assay (RIPA) buffer.
Samples were denatured by incubating at 95°C for 5 min. Samples were spun
in a benchtop centrifuge to minimise loss of evaporated sample before loading
alongside 5 µL of PageRuler™ prestained protein ladder onto Mini-PROTEAN
TGX SDS-polyacrylamide precast gel. Proteins were separated by
electrophoresis at 100 V in Tris-glycine running buffer; 25 mM Tris-Cl; 192
mM Glycine; 0.1% SDS, pH 8.3. Proteins were separated until the dye front
reached the bottom of the gel. Mini-PROTEAN® tetra vertical electrophoresis
cell (Bio-Rad) tank was used with an ice block to maintain temperature.
Separated proteins were transferred by western blotting to nitrocellulose
membrane using the Trans-Blot Turbo Transfer System on TURBO mode
(1704150, Bio-Rad). Transferred membranes were blocked in 5% (w/v ) BSA
in PBS-TWEEN®20, 0.1% (v/v ) (PBS-T) for 1 h to minimise non-specific
antibody binding. Blocked membranes were transferred to 50 mL tubes
containing primary antibody diluted in 5% BSA in PBS-T (Table 2.10) and
incubated overnight at 4°C. After incubation, membranes were washed with
PBS-T, three times for 5 min each. Membranes were incubated in the
appropriate fluorescent secondary antibody diluted in 5% BSA in PBS-T
(Table 2.10) in conical tubes, protected from light, for 1 h, RT. Unbound
secondary antibody was removed with three, 5 min washes in PBS-T. Specific
bands were detected using the Odyssey® CLx Imaging System and Image
Studio™ software.
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2.5 In vitro ALDH Activity Analysis
2.5.1 Recombinant ALDH1B1 Expression and Purification
His-tagged ALDH1B1 recombinant enzyme was expressed and purified by Dr
Zhiping Feng, James Chen laboratory, Stanford University.
Expression
Plasmid containing the DNA sequence encoding ALDH1B1
(pET15b-ALDH1B1) was transformed into TunerDE3 chemically competent
cells according to the manufacturer protocol. Single colonies were used to
inoculate 5 mL lysogeny broth (LB) supplemented with Ampicillin (100 µg/mL)
and Spectinomycin (50 µg/mL). Cells were grown at 37°C, overnight. Cultures
were transferred to 1 L of LB and once culture OD600 = 0.6, cultures were
induced with Isopropyl-β-D-thiogalactoside (IPTG) (0.5 mM final
concentration) and grown at 16°C overnight. Cultures, 250 mL/tube were
pelleted by centrifugation at 5000 rpm, 25 min, 4°C. Cultures were stored at
-20°C for ≈ 1 h.
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Purification
Cells were lysed with BugBuster Master Mix, 10 mL containing cOmplete™
ULTRA Protease Inhibitor. Cultures were rocked at RT for ≈ 20 min. Lysed
samples were spun down at 16000 x g at 4°C for 25 min. The soluble fraction
was retained and 2 mL of nickel-nitrilotriacetic acid (Ni-NTA) superflow
agarose resin was added. The resin and soluble fraction were incubated in 50
mL conical tube at 4°C for ≈ 1 h. The mixture was flowed through the column
for the resin to settle. Beads were washed with 40 mL buffer B1, followed by
buffer W1. Bound protein was eluted with 500 µL of buffer E1. Glycerol, 500
µL was added to each 500 µL fraction. Purified recombinant protein was
stored at -80°C in 1:1 (v/v ) glycerol and E1.
Binding buffer (B1): 500 mM sodium chloride, 20 mM sodium phosphate, 1
mM dithiothreitol, 20 mM imidazole, 5% glycerol, pH 7.4.
Wash buffer (W1): 500 mM sodium chloride, 20 mM sodium phosphate, 1 mM
dithiothreitol, 40 mM imidazole, 5% glycerol, pH 7.4.
Elution buffer (E1): 500 mM sodium chloride, 20 mM sodium phosphate, 1
mM dithiothreitol, 400 mM imidazole, 5% glycerol, pH 7.4.
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2.5.2 Recombinant ALDH2 Expression and Purification
His-tagged ALDH2 recombinant enzyme was expressed and purified by Dr
Matt Nowicki, Edinburgh Protein Production Facility, Edinburgh University.
Expression Plasmid containing the DNA sequence encoding ALDH2 (pET3a)
was transformed into C41 chemically competent cells according to the
manufacturer protocol. Single colonies were used to inoculate 2 mL LB
supplemented with Carbenicillin (100 µg/mL). Cultures were incubated at
37°C, 250 rpm for 7 h. Starter culture, 0.5 mL was incubated in pre-warmed
EnPresso® B media (2 media tablets, 25 µL Reagent A, 100 µg/mL
carbenicillin). Cultures were incubated overnight at 30°C, 250 rpm. Following
incubation, expression was induced by adding 1 mM IPTG and the media was
supplemented with 1 booster tablet and 25 µL Reagent A. Cultures remained
incubating at 30°C, 250 rpm for 24 h. Cells were harvested by centrifugation
at 4000 x g and the resultant pellets were flash frozen in liquid nitrogen and
stored at -80°C.
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Purification Cells were resuspended in lysis buffer (W2), 30 mL
containing cOmplete™ ULTRA Protease Inhibitor and 10 mg/mL DNase 1 (15
µL). Cells were lysed by mechanical lysis (25 kPsi, Constant Systems cell
disruptor). Lysed samples were spun down at 25000 x g at 4°C for 45 min.
The soluble fraction was filtered (0.2 µm) and loaded onto a HiTrap SP FF (1
mL, pre-equilibrated in W1 buffer) at a flow rate of 1 mL/min. The column was
washed with 20 column volumes (CV) of W2 buffer. Bound protein was eluted
through an E2 gradient; 6% E2, for 5 CV; 9% E2 for 10 CV; 9–26% for 10 CV;
26% E2 for 5 CV; 26–100% for 10 CV. Fractions associated with the ALDH2
were pooled and concentrated to 150 µL using a spin concentrator (30 kDa
cut-off). ALDH2 was further purified by gel filtration using a superdex200
10/300 column and buffer E2. ALDH2 eluted as a single peak with a retention
volume of 12.1 mL. The fractions containing ALDH2 (as analysed by
SDS-PAGE) were pooled to give a final concentration of 0.37 mg/mL (3 mL).
Purity was calculated to be >95% by analytical gel filtration and SDS-PAGE
density analysis.
Lysis and Wash buffer (W2): 100 mM sodium acetate, pH 5.0; 50 mM sodium
chloride.
Elution buffer (E2): 100 mM sodium acetate, pH 5.0; 1 M sodium chloride.
Gel filtration/enzyme buffer (F1): 20 mM HEPES, pH 7.5; 100 mM sodium
chloride; 1 mM dithiothreitol.
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2.5.3 ALDH Activity
2.5.3.1 Dehydrogenase
Purified His-tagged ALDH1B1 was diluted from glycerol stock to 25 µg/mL in
100 mM sodium phosphate buffer. 0.5 µg of ALDH1B1 (20 µL volume) was
added per well followed by pre-incubation with 20 µL 2-mercaptoethanol (5
mM) for 2 min. 5 mM NAD+, 1 mM MgCl2 in 100 mM sodium phosphate buffer
(20 µL) was added to the enzyme reaction and pre-incubated for 20 min.
5-nitrofurans or control compounds (daidzin, disulfiram) were diluted in DMSO
and 20 µL added to the enzyme reaction. Drugs were preincubated for 10
min. NADH standard curve was generated and background absorbance was
recorded at Ex/Em 340/460 nm. Acetaldehyde (5 mM, 20 µL) was used to
initiate the dehydrogenase reaction and NADH generated was recorded by
fluorescence emitted at Ex/Em 340/460 nm in kinetic mode for 30 min.
Daidzin and disulfiram (10 µM) were used as positive controls for ALDH
inhibition.
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Table 2.11: UV-Vis Settings for Analysis of Dehydrogenase Assay
Measurement Parameter Infinite® M200 Pro Settings
Plates Corning™ Costar™ 96 Flat Bottom




Mode Top (T) / Bottom (B)
z-position (top fluorescence) calculated from sample well
Excitation wavelength (λex) 340 nm
Emission wavelength (λem) 460 nm
Gain Determined by well containing 1 nmol NADH
Number of flashes 1
Settle time 0 ms
Lag time 0 µs
Integration time 20 µs
Reads per well 1
67 Chapter 2






































































































































































































































































































































Aldehydes, gene-drug interactions and cancer subpopulations
2.5.3.2 Esterase
Purified recombinant ALDH2 was diluted in HEPES buffer (60 nM/well) and
preincubated with 0.5 mM or 0.05 mM NAD+ in HEPES. 5-NFNs were
incubated with the enzyme for 20 min with shaking prior to reaction initiation.
4-Nitrophenol (4-NP) was serially diluted into wells of the reaction plate to
generate a 4-NP standard curve. 4-Nitrophenylacetate (4-NPA) was prepared
(4 mM in 6% (v/v ) DMSO) and was added to substrate wells at a final
concentration of ≈ 1 mM. Formation of 4-NP was monitored by measuring
absorbance at 405 nm. All experiments were performed in triplicate with 60
nM recombinant human ALDH2. All reactions were performed in a white
96-well plate with 50 µL final reaction volume. Absorbance was measured at
λ = 405 nm using the automated 96-well plate reader Infinite® M200 PRO
(Tecan, Switzerland) (Table 2.13). Enzymatic rates were determined using the
initial linear change of absorbance and all data analysed using Prism 7
(GraphPad).
Table 2.13: Fluorometer Settings for Analysis of Esterase Activity
Measurement Parameter Infinite® M200 Pro Settings
Plates Corning™ Costar™ 96 White Flat Bottom





Number of reads 25 ms
Settle time 0 ms
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2.6 ALDH Assays on Liver Tissue
2.6.1 Dehydrogenase
PicoProbe™ analysis of ALDH activity was performed on freshly extracted
protein from liver or PCLS in Tris-Cl buffer. The assay was performed
according to manufacturer protocol, with the exception that Tris-Cl buffer was
used instead of the kit assay buffer. Briefly, NADH standard curve was
prepared. Protein extracts from fresh liver were pre-incubated in wells
alongside substrate mix and small molecules (NFN1, NAZ, NFX) diluted in
DMSO. PCLS protein extracts were aliquotted into corresponding wells before
addition of PicoProbe™ in Tris-Cl buffer. Background control readings,
containing no addition of acetaldehyde were prepared. The dehydrogenase
reaction was initiated with acetaldehyde. For quantitation of ALDH activity,
fluorescence was recorded at Ex/Em 535/587 nm for 0 - 60 min. For analysis,
background readings were subtracted from sample readings and NADH
generated during the reaction time was interpolated from the NADH standard
curve.
Table 2.15: PicoProbe™ ALDH Activity Analysis
Reagent Supplier Cat No
PicoProbe™ BioVision K741-100
Corning™ 96-Well Black Polystyrene Microplate Sigma-Aldrich CLS3603
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2.7 ALDEFLUOR™ Staining and Flow Cytometry
A375 cells were seeded at a density of 250,000 cells per T175 flask. Cells
were harvested during growth phase. ALDEFLUOR™ assay was performed
according to the manufacturer protocol. Cells were harvested by trypsinisation
as described above. Cell number was determined using a haemocytometer
and staining non-viable cells with trypan blue; 10 µL of cell suspension was
added to 10 µL Trypan blue stain and 10 µL was loaded into each chamber of
the haemocytometer. Thirty million A375-Cas9 cells were incubated with
fluorescent Bodipy™-aminoacetaldehyde diethyl acetal (BAAA-DA) reagent
for 30 min at 37°C. To negatively control for FACS-analysis, cellular ALDH
activity was blocked with diethylamino-benzaldehyde (DEAB) and an
unstained sample of trypsinised cells was treated in parallel to the
ALDEFLUOR™ and DEAB-treated samples. ALDEFLUOR™-stained cells
were sorted using the BD FACSAria™ II (BD Biosciences). The top 5% and
bottom 5% of ALDEFLUOR™-stained cells were sorted by
fluorescence-activated cell sorting (FACS) into two populations and cells were
collected into DMEM containing 2% (v/v ) FBS in conical tubes on ice.
ALDEFLUOR™ was detected on 488 nm excitation and 525/50 nm BP filter
for detection. Dead cells were excluded using 12 µM propidium iodide
solution or 3 µM 4′,6-Diamidine-2′-phenylindole dihydrochloride (DAPI). Data
were analyzed using FlowJo software. For measurement of ALDEFLUOR™
staining of A375-ALDH1A3C21 cells, A375-ALDH1A3C21 and A375-Cas9 cells
were treated with ALDEFLUOR™ (and DEAB inhibitor/unstained control) as
above and quantitated using the BD LSRFortessa™ (BD Biosciences).
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Table 2.16: FACS ALDEFLUOR™ Analysis
Reagent Supplier Cat No
ALDEFLUOR™ kit STEMCELL™ Technologies 01700
DAPI, 1 mg/mL MBD0015 Sigma-Aldrich
Propidium iodide solution Sigma-Aldrich P4864
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2.8 RNA Extraction
Ribonucleic acids were purified from cell lines through phenol-chloroform
extraction according to the TRIzol™ manufacturer protocol. Briefly,
FACS-sorted cells were pelleted by centrifugation at 1000 rpm and the cell
pellet was resuspended in 0.75 mL of TRIzol™ per 5 million cells.
Alternatively, adherent monolayers of cells were directly lysed, after removal
of media, by addition of TRIzol™ to the culture flask. Cells were incubated
with TRIzol™ for 5 min to dissociate and solubilise nucleoproteins. Lysate
was transfered to LoBind tubes and homogenised by pipetting. Chloroform,
200 µL per 1 mL TRIzol™ was added to lysates to promote phase separation.
Samples were then bench vortexed, incubated for 5 min and centrifuged for
15 min at 12,000 x g, 4°C. The resulting aqueous phase was collected and
RNA precipitated from the aqueous phase with addition of isopropanol and
incubation for 10 min. Precipitated RNA was collected by centrifugation for 10
min at 13,000 x g, 4°C. The resulting RNA pellet was washed by
re-suspension in 75%ethanol, homogenised by bench vortex and centrifuged
at 13,000 x g, 4°C. The RNA pellet was air-dried and was resuspended in 50
µL RNase-Free water.
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Table 2.17: RNA Extraction
Reagent Supplier Cat No
TRIzol™ Invitrogen™ 15596018
Chloroform Fisher Scientific 10071970
Isopropanol Fisher Scientific 10215390
RNeasy MinElute Cleanup Kit Qiagen 74204
DNA LowBind Micro tube, 2 mL SARSTEDT 72.695.700
RNasin® Ribonuclease Inhibitor Promega N251B
LightCycler® 480 SYBR Green I Master Roche 23724620
SuperScript™ III Reverse Transcriptase Invitrogen™ 18080093
Invitrogen™ UltraPure™Water Fisher Scientific 11538646
Invitrogen™RNAlater™ Thermo Fisher Scientific AM7020
Ethanol absolute, ≥99.8% VWR Chemicals 437433T
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After preparation of total RNA from samples as described above, RNA
samples (2 µL, heated to 70°C for 2 min) were quality controlled with the
Agilent 2100 Bioanalyser System (Agilent Technologies, GS2938B) and
Agilent RNA 6000 Nano assay kit. Quality-controlled RNA samples were
submitted for library preparation and next generation RNA sequencing to the
Wellcome Trust Edinburgh Clinical Research Facility Genetics Department.
2.9.1.2 Library Preparation
Libraries were prepared from 500 ng of each total-RNA sample using the
TruSeq Stranded mRNA Library Kit according to manufacturer protocol.
Poly-A containing mRNA molecules were purified using poly-T oligo attached
magnetic beads. Following purification, mRNA was fragmented using divalent
cations under elevated temperature and primed with random hexamers.
Primed RNA fragments were reverse transcribed into first strand cDNA using
reverse transcriptase and random primers. RNA templates were removed and
a replacement strand synthesised incorporating dUTP in place of dTTP to
generate double stranded cDNA. The incorporation of dUTP in second strand
synthesis quenches the second strand during amplification as the polymerase
used in the assay is not incorporated past this nucleotide. AMPure XP beads
were then used to separate the ds cDNA from the second strand reaction mix,
providing blunt-ended cDNA. A single ’A’ nucleotide was added to the 3’ ends
of the blunt fragments to prevent them from ligating to another during the
subsequent adapter ligation reaction, and a corresponding single ’T’
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nucleotide on the 3’ end of the adapter provided a complementary overhang
for ligating the adapter to the fragment. Multiple indexing adapters were then
ligated to the ends of the ds cDNA to prepare them for hybridisation onto a
flow cell, before 12 cycles of PCR were used to selectively enrich those DNA
fragments that had adapter molecules on both ends and amplify the amount
of DNA in the library suitable for sequencing. After amplification libraries were
purified using AMPure XP beads.
2.9.1.3 Library Quality Control
Libraries were quantified by fluorometry using the Qubit dsDNA HS assay and
assessed for quality and fragment size using the Agilent Bioanalyser and High
Sensitivity DNA Analysis kit.
2.9.1.4 Sequencing
Sequencing was performed using the NextSeq 500/550 High-Output v2 kit on
the NextSeq 550 platform (Illumina Inc, SY-415-1002). Libraries were
combined in an equimolar pool based on the library quantification results and
run across a single High-Output Flow Cell.
Table 2.18: RNA-Sequencing
Reagent Supplier Cat No
Agilent RNA 6000 Nano assay kit Aligent 5067-1511
TruSeq® Stranded mRNA Library Prep Kit Illumina 20020594
Agencourt AMPure XP Beckman Coulter A63881
Bioanalyzer High Sensitivity DNA Analysis Aligent 5067-4626
NextSeq 500/550 High-Output v2 Kit Illumina FC-404-2002
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2.9.2 RNA-Seq Analysis Pipeline
2.9.2.1 FASTQ Generation
Basecall data produced by the NextSeq 550 was uploaded to BaseSpace
(Illumina). Basecall data is converted into FASTQ files to allow analysis using
a number of apps accessible directly through BaseSpace, or to download so
that alternative analysis pipelines can be used.
2.9.2.2 Read Quality Control
A 2 x 75 bp sequencing run on the Nextseq 550 using a high output flow cell
is expected to generate up to 400 M reads with a data quality of > 80% higher
than Q30, based on a cluster density of 170-230 K/mm2. When multiplexing 12
samples per flow cell we would therefore expect to see up to 33 M paired end
(PE) reads per sample.
The flow cell achieved a cluster density of 189 K/mm2 with 91.1% of clusters
passing quality filters (PF). The generated data had 93.2% >Q30. Coverage of
each sample was a little uneven, though all libraries sequenced generated >
28 M PE reads (Min: 28.9 M, Max: 49.9 M, Mean: 36.3 M). Table 2.19 provides
the number of clusters PF for each library, corresponding to the number of PE
reads.
2.9.2.3 Mapping Reads and Analysis
The matrix of RNA-seq unnormalised counts was mapped and DEG analysis
performed with the DESeq2 bioconductor package (Love et al., 2014) by
Graeme Grimes, MRC Human Genetics Unit, Edinburgh. I performed all
downstream analyses using RStudio (v 1.1.463).
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Table 2.19: Number of Clusters Passing Quality Filters per Sample
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2.10 Aldehyde Derivatisation and Quantification
2.10.1 Aldehyde Derivativatisation
Extended methods specific to each analytical step are described in Chapter 4.
2.10.1.1 Derivatisation
Mouse plasma and MS-grade water were used as matrices to test the
derivatisation of aldehydes with DNPH. Matrices were fortified with
acetaldehyde and/or the internal standard (d4-acetaldehyde). Fortified
samples (100 µL) were deproteinated by addition of 1 volume acetonitrile and
2.5 volumes methanol. Samples were centrifuged at 15000 x g, 15 min, 4°C
and the supernatant removed to glass vial. Acetaldehyde and
(d4-acetaldehyde) in the samples was derivatised by addition of a
molar-excess of DNPH in 6N (other solvents were tested as described in
chapter 4). The pH of each reaction mixture checked using pH indicator
paper. The pH of each reaction was increased to pH 4 using sodium acetate
solution. Derivatisation reactions proceeded for 1 h at RT on a desktop plate
shaker. The derivatisation reaction was stopped by altering the pH with
addition of 3 volumes sodium acetate. Samples were vacuum concentrated
using an Eppendorf™ Concentrator Plus (Fisher Scientific, 12884952) and
resulting samples were resuspended to their initial volume before
chromatographic analysis.
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Table 2.20: Aldehydes and Aldehyde-2,4-DNPH Reference Standards
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2.10.2 LC-MS Analysis of Derivatised Aldehydes
Extended methods are reported in Chapter 4. All reagents used were of HPLC
grade.
2.10.2.1 Analysis of Commercial Standards
Freshly harvested mouse plasma and MS-grade water was spiked with the
aldehyde-DNPH standards acetaldehyde-2,4-DNPH,
formaldehyde-2,4-DNPH and propionaldehyde-2,4-DNPH. Samples were
spiked with aldehyde-DNPH standards to a final concentration of 10 µM (1:9
(v/v ) acetonitrile:water). Samples were deproteinated using 1 volume
acetonitrile and 2.5 volumes methanol followed by centrifugation at 15000 x g,
15 min, 4°C. Supernatant was vacuum concentrated using an Eppendorf™
Concentrator Plus (Fisher Scientific, 12884952) and resulting pellets were
resuspended to their initial volume in 2% (v/v ) acetonitrile before
chromatographic analysis.
2.10.2.2 LC-MS Instrumentation
Samples were analysed with the following instrumentation:
Table 2.22: LC-MS Instrumentation
Column LC-MS
Accucore™ C18 column UltiMate™3000 HPLC (Thermo)
80Å, 2.6 µm, 2.1 mm x 100 mm Q Exactive™Orbitrap system (Thermo)
ACQUITY UPLC HSS T3 Column Acquity™Ultra Performance LC (Waters)
100 Å, 1.8 µm, 2.1 mm x 150 mm QTrap 5500 (AB Sciex)
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2.10.2.3 LC Conditions
Table 2.23: Chromatographic Gradient on Accucore™
C18 column with UltiMate™3000 HPLC
Retention (min) Flow (mL/min) % A % B Curve
0 0.05 98 2 5
0 0.3 80 20 5
0.3 0.3 80 20 5
0.5 0.3 80 20 5
4 0.3 70 30 5
7 0.3 10 90 5
9.5 0.3 10 90 5
10 0.3 80 20 5
12 0.3 80 20 5
12.1 0.02 80 20 5
Mobile Phase A, MS-grade water; Mobile Phase B,
acetonitrile.
Gradient flow rate, 0.3 mL/min.
Column temp, 45°C.
Column Type, Accucore™ C18 LC Column 80Å, 2.6 µm, 2.1
mm X 30 mm. Column Type, Accucore™ C18 LC Column
80Å, 2.6 µm, 2.1 mm X 30 mm.
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Table 2.24: Chromatographic Gradient on ACQUITY
T3 column with Acquity™Ultra
Performance LC
Retention (min) Flow (mL/min) %A %B Curve
1.5 0.4 75 15 5
2.00 0.4 15 85 5
5.00 0.4 15 85 5
5.50 0.4 85 15 5
7.50 0.4 85 15 5
Buffer A, MS-grade water; Buffer B, acetonitrile.
Gradient flow rate = 0.4 mL/min
Column temp = 45°C
Column Type = Waters ACQUITY UPLC HSS T3 Column,
100Å, 1.8 µm, 2.1 mm X 150 mm.
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2.10.2.4 MS Conditions
Table 2.25: MS Conditions for Analysis of Aldehyde-DNPHs on
Orbitrap MS
Parameter





Maximum Injection Time 200 ms
Scan Range 206-212 m/z, 220-226 m/z, 234-240 m/z
Spectrum Data Type Profile
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2.10.2.5 Data Analysis
HPLC-MS data from the Q-Exactive Mass Spectrometer was acquired with
CHROMELEON™ and XCalibur 4.0 (Thermo). AssayR was used for
generation of histograms to represent absolute peak area for analysis of
QE-generated HPLC-MS data (Wills et al., 2017). UPLC-MS Data from the
QTrap 5500 was acquired and processed using Analyst 3.0 software (AB
Sciex).
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2.11 Laboratory Animal Work
2.11.1 Facilities and Project License
All animal work was conducted in accordance to the UK Home Office Animals
(Scientific Procedures) Act (1986), under Home Office project licence
(70/7950 and PD702DCD2) and personal licences (IBC155803) with approval
from Veterinary services at the Human Genetics Unit Biomedical Research
Facility.
2.11.2 Mouse Strain Origins and Husbandry
The ALDH1b1 mouse line was provided by Prof. M.J. Arends (CRUK,
Edinburgh). Aldh1b1-/- mice possess a complete knockout of exon 2 of the
murine Aldh1b1 gene. The Aldh1b1-/- mouse line was generated with a
gene-trap approach that uses the knockout-first strategy (Skarnes et al.,
2011). The knockout-first allele contains a gene trap cassette and neomycin
cassette driven by a floxed promoter that was inserted into the second intron
of the Aldh1b1 gene. The knockout-first allele was converted to a conditional
allele by Flp recombinase and the tm1d (complete knockout) mouse line was
generated after crossing Flp+ mice with Cre transgenic mice to delete the
floxed exon. The Aldh1b1 mouse line was maintained on the C57BL/6 line for
five generations. Mice were fed a standard chow diet and water ad libitum
and housed in conventional barrier cages with enrichment. Mice were kept on
a 12 hour light-dark cycle: During the dark cycle, lights were not used and
researchers and technicians did not enter the mouse room.
89 Chapter 2
Aldehydes, gene-drug interactions and cancer subpopulations
2.11.3 Mouse Genotyping
2.11.3.1 DNA extraction, Amplification and Analysis
Table 2.27: DNA Extraction and Analysis
Reagent Supplier Cat No
QIAprep spin miniprep kit Qiagen 27106
DirectPCR Lysis Reagent (Ear) Viagen Biotech 402-E
PCR 8 Tube Strips, 0.2 mL Alpha Laboratories LW2570
DreamTaq Green PCR Master Mix (2X) Thermo Scientific™ K1081
UltraPure™ Agarose Invitrogen™ 15510027
Quick-Load® 1 kb DNA Ladder New England BioLabs N0468S
Quick-Load® Purple 100 bp DNA Ladder NEB® N0551S
SYBR Safe DNA gel stain Invitrogen™ S33102
PCR genotyping was performed on ear biopsies of Aldh1b1 mice. Ear
biopsies, 0.2 cm were digested in 100 µL of DirectPCR ear lysis reagent
containing 0.4 mg/mL Proteinase K in autoclaved 1.5 mL Eppendorf® tubes.
Ears were lysed overnight in a water bath at 55°C followed by Proteinase K
inactivation for 1 h at 85°C. Crude lysates were stored at -20°C. PCR
reactions were set up according to Table 2.29 and DNA amplified through
PCR with cycles detailed in Table 2.30. Amplified PCR product was separated
on agarose gel. Agarose gels were prepared with agarose in 1X
Tris/Borate/EDTA (TBE) buffer. The PCR product of Aldh1b1 reaction 1 was
separated on 2% (w/v ) agarose gel and the PCR product of Aldh1b1 reaction
2 was separated on 3% (w/v ) agarose gel. SYBR Safe DNA stain was added
to molten agarose (1:10000) before casting the gel to enable DNA
visualisation under Ultraviolet (UV) light. Five microlitres of DNA ladder (100
bp / 1 kb) was loaded onto each well to enable sizing of PCR products.
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Mini-Sub® GT Cell (Bio-Rad, 1704406) reservoir was filled with 1X TBE and
the solidified agarose gel. PCR reactions at end point were loaded directly
into wells before electrophoretic separation at 100 V in 1X TBE buffer until
adequate separation was achieved. Resolved DNA was photographed under
UV light using the CHEMI Genius2 BioImaging System (Syngene) and
GeneSnap™ analysis tool. A representative image of the presence of
targeted homozygous knockout, heterozygous knockout or wildtype Aldh1b1
alleles is in Figure 2.3.
Figure 2.3: Genotyping for ALDH1B1 allele status
Gel 1: PCR reactions of earclip DNA for the floxed allele. Lane 1,
DNA Ladder; Lane 2, wild-type, heterozygous; Lane 3,
homozygous. Gel 2: PCR Reaction of earclip DNA for the floxed
allele.
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Table 2.28: Genotyping Primers





Table 2.29: Genotyping PCR Reactions
Reagent Volume (µL)
Aldh1b1 Reaction 1 20
FL065 forward primer 0.5
FL066 reverse primer 5
2X Taq Polymerase 10
Water 3.5
DNA template 1
Aldh1b1 Reaction 2 20
Tm1c forward primer 0.2
FL_LR reverse primer 0.2
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Table 2.30: Genotyping PCR Cycles
PCR Step Temperature (°C) Time (s) number of cycles
Aldh1b1 Reaction 1
Preheat 95 120 1
Denaturation 95 30 32
Annealing 58 30
Extension 72 90
Termination 72 300 1
4 ∞ 1
Aldh1b1 Reaction 2
Preheat 95 120 1
Denaturation 95 30 35
Annealing 58 30
Extension 72 180
Termination 72 300 1
4 ∞ 1
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2.12 Mouse In Vivo Studies
2.12.1 Nifuroxazide and Ethanol Cotreatment
ALDH1b1 heterozygous and homozygous mutant mice on C57BL/6
background at 6-8 weeks were administered over seven days with 20%
ethanol in drinking water, which is well tolerated in mice. On the eighth day,
ethanol treatment was continued and nifuroxazide was administered at a dose
of 150 mg/kg in sunflower oil for four days. Mice were weighed and general
health was monitored daily. At the experimental end-point, mice were culled
through schedule 1 exposure to carbon dioxide at rising concentration.
Terminal blood collection was performed by puncture of the inferior vena
cava, to allow collection of larger blood volumes than cardiac puncture. Blood
was stored in pre-cooled heparin-coated tubes on ice but was processed
under cold conditions and as rapidly as possible to minimise aldehyde loss
from samples.
2.13 Acetaldehyde Plasma Detection
Freshly-harvested plasma was prepared from heparinized blood with
centrifugation at 3000 × g for 15 min, 4°C immediately after withdrawal.
Acetaldehyde levels in the plasma were analysed immediately to ensure
maximal recovery of acetaldehyde in samples. Plasma acetaldehyde
concentrations were determined using an enzymatic acetaldehyde assay.
Samples were assayed according to the manufacturer instructions, and 50 µL
of plasma used for one reaction per well.
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Table 2.31: Mouse In Vivo studies and Blood Collection
Reagent Supplier Catalogue Number
Ethanol absolute ≥99.8% VWR Chemicals 437433T
B. Braun Sterican 25 gauge needle VWR 465785, 612-0153
BD PlastiPak™ Syringe Fisher Scientific 15544835
Lithium Heparin Blood Collection Tube Greiner Bio-One 459084
Nifuroxazide Millipore 481984
Supelco™ sunflower seed oil Sigma-Aldrich 47123
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3.1 Introduction
3.1.1 Overview
The 5-nitrofurans (5-NFNs) are a class of prodrugs with antibiotic and
antiparasitic activities. Interactions between ALDH and 5-nitrofurans are
critical mediators of 5-nitrofuran-induced melanocyte cell death in zebrafish,
where is has been shown that the zebrafish Aldh2b (Aldh2) enzyme
bio-activate 5-nitrofuran (nifurtimox, NFN1) prodrugs (Zhou et al., 2012).
Furthermore, 5-nitrofurans (nifurtimox, NFN1) have been indicated as
competitive substrates for human ALDH2 in vitro (Zhou et al., 2012). While
the Patton laboratory Zhou et al. (2012) has investigated ALDH2-mediated
bio-activation of 5-nitrofuran prodrugs in zebrafish, the relevance of this
interaction in mammals, its involvement in mechanisms underpinning
5-nitrofuran side effects and how genetic mutations alter the ALDH:5-NFN
interaction remains unknown.
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3.1.2 Aims
The Patton laboratory has previously demonstrated bio-activation of
5-nitrofurans by zebrafish Aldh2b. I hypothesised that 5-nitrofurans inhibit the
activity of ALDH enzymes expressed in mammalian liver and as a
consequence, alter the metabolism of endogenous ALDH substrates. This
first results chapter encompasses this aim to explore the potential for
ALDH:5-NFN interactions in mammalian systems. To this end, the
experiments in this chapter were performed under three objectives:
1. Identify protein-drug interactions between ALDH and 5-nitrofuran in vivo
and ex vivo.
To achieve this objective, studies to establish the effect of 5-nitrofurans
on enzyme activity were performed on human recombinant ALDH
proteins.
2. Investigate whether ALDH:5-NFN protein-drug interactions are
physiologically relevant and occur with ALDH enzymes expressed in the
liver.
To fulfil this objective, precision cut liver slices were developed and
characterised as mammalian ex vivo tools to study ALDH:gene-drug
interactions. ALDH isoform transcript and protein expression in liver
slices was analysed and methods of detecting ALDH activity in liver
extracts and slices were applied to explore to the effects of the
5-nitrofurans ex vivo.
3. Determine the impact of 5-NFN and ethanol exposure on
ALDH-mediated pathways in vivo and the involvement of the ALDH
isoform Aldh1b1 on the ALDH:5-NFN interaction. Studies on Aldh1b1
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knockout mice were used to elucidate the in vivo impact of 5-NFN
exposure on ALDH enzymes and to address the importance of the
ALDH1B1 isoform on the ALDH:5-NFN interaction in vivo. To fulfil this
objective, ELISA-based aldehyde analysis was used to determine the
response to ethanol and nifuroxazide-exposure in vivo through
monitoring the relative abundance of circulating plasma acetaldehyde.
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3.2 Results
3.2.1 Nitrofurans are Competitive Substrates for ALDH
Enzymes In Vitro
Given that 5-nitrofurans are bioactivated by Aldh2b in zebrafish melanocytes
(Zhou et al., 2012), and ALDH enzymes are expressed across species in liver,
I hypothesised that 5-nitrofurans bind to ALDH enzymes present in mammalian
liver. ALDH2 and ALDH1B1 were chosen as candidate targets of 5-nitrofurans
in mammals. These candidates were chosen because:
• Zebrafish ALDH2b is homologous to mouse/human ALDH2.
• ALDH1B1 and ALDH2 isoforms share a high degree of sequence
similarity and substrate specificity: ALDH2 and ALDH1B1 are two main
enzymes involved in acetaldehyde metabolism.
• Patients treated with the 5-NFN, nifurtimox are intolerant to ethanol,
which when metabolised, gives rise to acetaldehyde, the main substrate
of ALDH2 and ALDH1B1 enzymes.
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3.2.1.1 ALDH Dehydrogenase Activity
To determine whether 5-nitrofurans interact with ALDH1B1, recombinant
ALDH1B1 protein was tested in an in vitro dehydrogenase activity assay. The
assay entails incubation of recombinant ALDH1B1 or ALDH2 enzyme with
5-nitrofurans, followed by addition of the endogenous ALDH1B1/2 substrate,
acetaldehyde. Metabolism of acetaldehyde by ALDH enzymes is NAD+
(nicotinamide adenine dinucleotide) dependent; during conversion of
acetaldehyde to acetic acid, NAD+ is reduced to NADH. NADH production can
be quantified by monitoring sample absorbance at 360 nm using
ultraviolet-visible spectroscopy (UV-Vis). Alternatively, NADH can be coupled
to PicoProbe™, a fluorescent NADH-binding probe which can be quantified
with fluorescence detection (Ex/Em = 535/587 nm). Together, these methods
of quantifying NADH generation provide a useful tool to analyse ALDH activity
(Figure 3.1). Incubation of ALDH1B1 protein with 5-nitrofurans resulted in
concentration-dependent and drug-specific inhibition of the dehydrogenase
activity of ALDH1B1 (Figure 3.2). NFN1 and NFX induced inhibition of
ALDH1B1 activity, whereas NAZ did not induce significant inhibitory effects.
The pan-ALDH inhibitor disulfiram significantly inhibited ALDH1B1 activity and
the selective ALDH2 inhibitor daidzin also inhibited ALDH1B1 activity, albeit
not the the same extent as disulfiram.
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Figure 3.1: Quantification of ALDH Dehydrogenase Activity
ALDH enzymes (isoforms 1A1, 1B1, 2) catalyse metabolism of
acetaldehyde to acetic acid. This reaction is NAD+-dependent.
During oxidation of acetaldehyde substrate, NAD+ is reduced to
NADH. NADH is used as a readout of ALDH activity. NADH can
be quantified by UV-Vis at 360 nm or with PicoProbe™-induced
fluorescence at excitation/emission 535/587 nm.
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Figure 3.2: 5-Nitrofurans Inhibit the Dehydrogenase Activity of ALDH1B1
The effect of 5-nitrofurans on ALDH1B1 activity was tested
through incubation of 0.5 µg ALDH1B1 with Mg2+ and NAD+ with
the 5-NFNs; NFN1, nifuroxazide (NAZ), nifurtimox (NFX) (5 µM,
10 µM). The dehydrogenase reaction was initiated with the
addition of 1 mM acetaldehyde and reduction of NAD+ to NADH
was quantified with the excitation/emission pair 340/460 nm. All
reactions were performed in triplicate wells per condition and
ANOVA used to test statistical significance. Error bars represent
standard deviation.
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3.2.2 ALDH Esterase Activity
Although designated the aldehyde dehydrogenase family, the enzymatic
activity of ALDHs is not limited to dehydrogenase action on aldehyde
substrates. The ALDH enzymes have multiple additional enzymatic activities
including esterase functions. I hypothesised that other ALDH enzymatic
activities, other than dehydrogenase activity would also be disrupted upon
exposure to 5-nitrofurans. To determine whether 5-nitrofurans inhibit the
esterase activity of ALDH2, recombinant ALDH2 was subjected to an in vitro
esterase activity assay: Recombinant ALDH2 enzyme was incubated with
5-nitrofurans, followed by reaction initiation with ALDH esterase substrate.
Currently, there are no identified endogenous ester substrates of ALDH
enzymes, so the ester, 4-nitrophenylacetate (4-NPA) was used as a substrate.
For analysis of esterase activity, the substrate 4-NPA is converted to 4-NP,
which absorbs at 405 nm, so affords quantification by UV-Vis (Figure 3.3).
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Figure 3.3: Quantification of ALDH Esterase Activity
ALDH enzymes catalyse conversion of 4-nitrophenylacetate
(4-NPA) to 4-nitrophenol (4-NP). Generation of 4-NP by active
ALDH enzyme can be measured by UV-Vis absorbance at 405 nm
and used to quantify ALDH esterase activity.
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3.2.2.1 ALDH Esterase Dynamics
Determining ALDH enzyme kinetics
To accurately determine the effects of tested compounds on esterase activity,
ALDH enzyme velocity was studied. For this, it was important to establish
reaction conditions where the ALDH2 enzyme exhibited linear kinetics.
ALDH2 substrate saturation dynamics were measured by incubating
recombinant ALDH2 protein with differing concentrations of the esterase
substrate, 4-NPA. Increased absorbance at 405 nm, representing 4-NP
production by ALDH2 was tracked over a 40 min timescale (Figure 3.5).
The resulting enzyme reaction curves demonstrated increases in
absorbance at 405 nm over the time course. Furthermore, higher
concentrations of 4-NPA yielded corresponding increases in absorbance at
405 nm, reflecting accumulation of the 4-NP product. Reassuringly, under
these reaction conditions, turnover of substrate by ALDH enzyme was
concentration-dependent. Given that the highest change in absorbance was
observed with 700 µM 4-NPA and that at this substrate concentration, linear
enzyme activity was retained for the reaction time, 700 µM 4-NPA was used
for subsequent esterase activity experiments. Notably, comparatively low
absorbance values were detected for the initial 500 s of the reaction.
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Figure 3.4: ALDH2 Ester Substrate Dynamics
Production of 4-NP by recombinant ALDH2 with increasing 4-NPA
substrate concentrations. Generation of 4-NP was determined by
measuring absorbance at 405 nm with 30 s intervals. Data points
are mean of 3 technical replicates.*This experiment was
performed with honours student, Marija Zarocsinceva under my
direct supervision.
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Determining molar extinction coefficients
For all experiments, a standard curve of known 4-NP concentration alongside
corresponding absorbance was generated. This enabled interpolation of the
amount of 4-NP generated by ALDH2 during the experimental procedure (3.5).
To determine the molar extinction coefficient, ε of 4-NP, Beer-Lambert law (A =
εcl) was applied to the absorbance values (ε = 3400 M-1 cm-1) and path length,
(l) of 0.2.


















Figure 3.5: 4-Nitrophenol Standard Curve (405 nm)
Absorbance at 405 nm plotted against known 4-NP concentrations
(100 - 800 µM). Data points are the mean of 3 technical replicates,
error bars represent standard deviation. *This experiment was
performed with honours student, Marija Zarocsinceva under my
direct supervision.
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Absorbance Spectra of Compounds
To confirm that compounds to be tested for esterase inhibition did not have
intrinsic absorbance that would interfere with UV-Vis detection of 4-NP, the
absorbance of several nitrofurans and the esterase inhibitor, Aldi-2 was
evaluated. Absorbance of the compounds was quantified between 230 nm
and 700 nm at 5 nm intervals (Figure 3.6). None of the tested compounds
absorbed at the 405 nm wavelength used for monitoring 4-NP (reporter of
esterase activity) and so the effect of compounds on ALDH esterase activity
could be investigated.
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Figure 3.6: Absorbance Spectra of Compounds Tested for Inhibitory
Action on ALDH Esterase Activity
The 5-nitrofurans; nifurtimox (NFX), nifuroxazide (NAZ), tool
5-NFN compound (NFN1), vehicle (DMSO) and esterase inhibitor
(Aldi-2) did not absorb at wavelengths used for the esterase assay
(405 nm) and so the effects of these compounds on esterase
inhibition could be measured using 4-NPA metabolism as a
readout. Spectra measured λ= 700 – 230 nm. Data points are the
mean of 3 technical replicates, error bars represent standard
deviation. *This experiment was performed by honours student,
Marija Zarocsinceva under my direct supervision.
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3.2.3 ALDH Esterase Activity is Enhanced by Oxidised
Nicotinamide Adenine Dinucleotide
The dehydrogenase activity of ALDH2 is NAD+-dependent. To decipher
whether the esterase activity of ALDH2 also required the NAD+ co-factor, the
rate of 4-NP production by ALDH2 under varying concentrations of NAD+ was
determined (Figure 3.7). In the absence of NAD+, ALDH2 generated 4-NP
from 4-NPA. Addition of NAD+ at 0.05 mM and 0.5 mM enhanced the esterase
activity of ALDH2: Under these NAD+ concentrations, the rate of 4-NP
production increased by 26% (P = 0.0023) and 66% (P = 0.0010),
respectively when compared to NAD+-deficient conditions.
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Figure 3.7: The Esterase Activity of ALDH2 is Enhanced By NAD+
Recombinant ALDH2 was incubated with 4-NPA as substrate.
Generation of 4-NP was monitored over 40 min. The possibility of
background interfering absorbance was corrected for by
subtracting absorbance in samples not containing substrate
(4-NPA) from substrate-containing samples. Rate of 4-NP
generation and ALDH esterase activity was determined by change
in absorbance / (time x mg protein). The presence of NAD+ at
concentrations of 0.05 mM and 0.5 mM led to increased 4-NP
production by 26% (P = 0.0023) and 66% (P = 0.0010),
respectively. Data points are the mean of 3 technical replicates,
error bars represent standard deviation. Statistical significance
tested by unpaired t-test. *This experiment was performed by
honours student, Marija Zarocsinceva under my direct
supervision.
112 Chapter 3
Aldehydes, gene-drug interactions and cancer subpopulations
3.2.4 Nitrofurans Inhibit the Esterase Activity of
Recombinant ALDH2
To determine whether 5-nitrofurans inhibit ALDH2 and disrupt the enzymatic
capacity of ALDH to metabolise ester substrates, recombinant ALDH2 was
subjected to an in vitro esterase activity assay in the presence of 5-nitrofurans
or control compounds using the esterase substrate, 4-NPA (Figure 3.8).
Reassuringly, the ALDH2 esterase inhibitor, Aldi-2 significantly ablated
generation of 4-NP compared to DMSO control (P <0.0001). The tool
nitrofuran compound, NFN1 exhibited significant concentration-dependent
inhibition of ALDH2 esterase activity at 3 µM (P = 0.0001) and 100-fold lower,
30 nM concentration (P = 0.0012).
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Figure 3.8: NFN1 inhibits ALDH2 esterase activity
Recombinant ALDH2 was incubated with 4-NPA as substrate with
NFN1 (10 nm – 3 µM) or vehicle (DMSO 1.2%). Generation of
4-NP was monitored over 40 min. The possibility of background
interfering absorbance was corrected for by subtracting
absorbance in samples not containing substrate (4-NPA) from
substrate-containing samples. Data points are the mean of 3
technical replicates, error bars represent standard deviation.
Statistical significance tested by unpaired t-test. *This experiment
was performed by honours student, Marija Zarocsinceva under my
direct supervision.
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3.2.5 ALDH Transcript Expression in Mammalian Liver
To address which ALDH isoforms are expressed in mammalian liver and to
confirm that ALDH1B1 and ALDH2 proteins are expressed in liver and
therefore could potentially be targets of 5-nitrofurans, transcript expression of
the 19 and 21 ALDH genes was probed in human HepG2 and mouse liver
respectively. Murine ALDH transcripts were probed similarly using the
BioGPS data set available at code GeneAtlas MOE430, gcrma. The ALDH
transcript most abundantly expressed in mouse liver from this stage is
ALDH1A1 (RALDH1) with ALDH1B1 and ALDH2 also expressed.
By analysing the transcript levels of a liver cancer cell line, HepG2, the
same ALDH isoforms were seen enriched in this tissue (Figure 3.9). Of all 19
ALDH enzymes expressed in the HepG2 cell line, ALDH1A1 (RALDH1) had
the highest expression level, similar to in mouse. The previously-characterised
acetaldehyde-metabolising ALDH enzymes, ALDH1A1, ALDH1B1 and ALDH2
were all expressed in the HepG2 cell line.
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Figure 3.9: Expression of ALDH Isoforms in the HepG2 Cell Line
Transcriptional levels of ALDH isoforms in the HepG2 in vitro
cultured cell line according to the Human Protein Atlas database.
ALDH1B1 and ALDH2 genes are both expressed in HepG2
cells.Data curated from the Human Protein Atlas (Uhlén et al.,
2015). Isoforms plotted by expression level. If the TPM value
exceeds 1, it is generally accepted that this level of transcript
results in functional expression of protein.
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Figure 3.10: Expression of ALDH Isoforms in Mouse Liver
Transcript levels of ALDH genes in 6-8 week C57BL/6 mouse
liver. ALDH1B1 and ALDH2 genes are both expressed in the
liver of C57BL/6 mice. Data curated from BioGPS-deposited
data. Error bars represent standard deviation.
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3.2.6 ALDH Protein Expression and Activity in Mammalian
Liver, Ex Vivo
To validate these computational data sets and to ensure that precision cut liver
slices derived from C57BL/6 mice were viable tools to explore ex vivo gene-
drug interactions involving ALDH, ALDH expression and activity in precision
cut liver slices was analysed using ALDH enzymatic activity assays and was
complemented with western blot methods.
Precision cut liver slices were analysed for their expression of ALDH1B1
and ALDH2 protein following 24 h culture (Figure 3.11). These isoforms
yielded intense-staining bands at the respective positions for ALDH1B1 and
ALDH2, 57 kDa and 56 kDa and so I explored ALDH:5-NFN interactions using
this experimental model.
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Figure 3.11: Expression of ALDH Isoforms in Mouse Precision Cut Liver
Slices
Protein levels of ALDH1B1 (57 kDa) and ALDH2 (56 kDa)
isoforms in precision cut liver slices from 6-8 week C57BL/6
mice. GAPDH loading control (37 kDa).
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3.2.7 Nitrofurans are Competitive Substrates of ALDH in
Mammalian Liver
Given that ALDH enzymes are expressed in human and mouse liver and the
main organ responsible for nitrofuran metabolism and elimination is the liver,
the possibility of an interaction between 5-nitrofurans and ALDHs, and
consequence on ALDH enzymatic activity in live liver tissues was examined.
3.2.7.1 Nitrofurans are Competitive Substrates of ALDH in Mammalian
Liver, In Vitro
First, whole liver extracts were prepared from the liver of C57BL/6 mice. For
liver preparation, protein samples were prepared from the left lateral lobe
(Figure 2.2). Left and right lateral lobes have similar ALDH activity when
tested with PicoProbe™assay (Figure 3.12). For testing 5-NFN compounds
and for consistency, the left lateral lobe was chosen to prepare protein
extracts as this is the larger of both lobes. Extracts from the left lateral liver
lobe were incubated with different nitrofuran compounds, nifurtimox (NFX),
nifuroxazide (NAZ) and NFN1. Following incubation, the ALDH activity of liver
extracts was tested by PicoProbe™ assay (Figure 3.13). Exposure of liver
extracts to 5-NFNs resulted in dose dependent inhibition of ALDH activity.
NFN1 demonstrated the most potent inhibition of acetaldehyde-metabolising
ALDH enzymes, followed by NFX and NAZ.
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Figure 3.12: ALDH activity in Mouse Lateral Liver Lobes
Liver tissue samples from the left and right lateral lobes of 6-8
week C57BL/6 mice were prepared and endogenous ALDH
activity monitored by PicoProbe™assay.
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Figure 3.13: 5-NFNs Inhibit ALDH activity in Liver Extracts In Vitro
Liver tissue protein extracts prepared from the left lateral lobe of
6-8 week C57BL/6 mice were incubated with NFN compounds
before analysis of ALDH activity via PicoProbe™assay. Extracts
exhibited concentration-dependent reduction in ALDH activity
when incubated with the 5-NFNs, NFN1 and NFX. Data points
are the mean of 3 technical replicates. Statistical significance
was tested by ANOVA. Error bars represent the standard error of
the mean.
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3.2.7.2 Nitrofurans are Competitive Substrates of ALDH in Mammalian
Liver, Ex Vivo
To test whether 5-NFNs maintained inhibitory activity against ALDH enzymes
in live tissue, precision cut liver slices were used as an ex vivo tool. Precision
cut liver slices (PCLS) were prepared from the left lateral liver lobe of 6-8 week
C57BL/6 mice (Figure 3.14) and incubated for 24 h with NFN1 (Figure 3.15).
NFN1 exhibited concentration-dependent reduction in ALDH activity of live, ex
vivo tissue slices.
Figure 3.14: Preparation of Precision Cut Liver Slices
PCLS were prepared from the left lateral lobe of 6-8 week
C57BL/6 mice and incubated with 5-NFN compounds before
analysis of ALDH activity via PicoProbe™ ALDH assay.
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Figure 3.15: NFN1 Decreases ALDH Activity in PCLS
PCLS were prepared from the left lateral lobe of 6-8 week
C57BL/6 mice and incubated with NFN compounds at 5 µM and
10 µM concentration for 24 h before analysis of ALDH activity via
PicoProbe™ALDH assay. Data points are the mean of 3 PCLS
replicates, performed with three picoprobe technical replicates.
Error bars represent standard deviation. Statistical significance
was tested by ANOVA.
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3.2.7.3 ALDH Substrates Increase the Cytotoxic Effects of 5-NFNs on
Liver Cells
Given that incubation of liver tissue with 5-NFNs resulted in
concentration-dependent reduction of ALDH activity, the potential of ALDH
substrates in increasing the cytotoxic effects of 5-NFNs was addressed.
HepG2 cells have active ALDH metabolism when measured through
ALDEFLUOR™ (Figure 3.16A) and expression of the ALDH2 isoform was
confirmed through western blotting (Figure 3.16B). Three day incubation of
5-NFNs in presence or absence of 2.5 mM acetaldehyde, in combination with
different concentrations of NFN1 led to a four-fold reduction of the EC50 for
NFN1 from 1.04 x 10-6 M to 2.26 x 10-7 M, indicating that acetaldehyde
invokes sensitisation of HepG2 cells to the cytotoxic effects of NFN1 (Figure
3.17).
To establish whether this sensitisation effect was the result of synergistic
or additive effects of acetaldehyde and NFN1 on the cell line, model-based
quantification of drug combinations was performed. BLISS, HSA and LOEWE
dose-response models were used to quantify whether synergistic or
antagonistic interactions underlied the cytotoxicity of acetaldehyde and NFN1
in HepG2 cells. Dose response matrices and surface models generated from
all mathematical models tested indicate enhanced cytotoxicity at the highest
concentration of acetaldehyde and NFN1. The interaction between
acetaldehyde and NFN1 is synergistic (synergy value > 10) at 10 µM NFN1
and this synergy is most prevalent when coupled with higher concentrations
of acetaldehyde. At lower concentrations of 5-NFN and acetaldehyde, the
interaction tends towards additivity ( -10 < synergy value < 10) or antagonism
(synergy value < -10).
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Figure 3.16: HepG2 Cells Express ALDH2 and Exhibit Proficient ALDH
Activity
A. HepG2 cells metabolise the BAAA substrate of the
ALDEFLUOR™ assay, a reporter of ALDH activity.
BWestern blotting of cell lysate reveals expression of ALDH2
protein.
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Figure 3.17: Acetaldehyde Increases the Cytotoxic Effects of 5-NFNs on
ALDH-Expressing Liver Cells
A. Exposure of HepG2 cells to 2.5 mM acetaldehyde does not
significantly impact upon cell viability. Statistical significance was
tested by unpaired t-test (N=6). Error bars represent standard
error of the mean.
B. Exposure of HepG2 cells to acetaldehyde (2.5 mM) sensitises
cells to the cytotoxic effects of NFN1. Statistical significance was
tested by Ordinary Two-way ANOVA (N=6). Error bars represent
standard error of the mean.
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Figure 3.18: Mapping Synergistic Interactions Between Acetaldehyde
and NFN1 in HepG2 Cells
BLISS, HSA and LOEWE dose-response models were used to
determine whether synergistic or antagonistic interactions
underlied the cytotoxicity of acetaldehyde and NFN1 in HepG2
cells. P<0.05 (*), P<0.01 (**), P<0.001(***).
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3.2.8 The Effect of 5-Nitrofurans In Vivo
3.2.8.1 The Effect of 5-Nitrofurans on ALDH activity In Vivo
As an interaction between ALDH and 5-NFNs was observed in vitro and ex
vivo in liver, it was hypothesised that delivery of 5-NFNs in vivo would alter
ALDH activity. The potential for ALDH:5-NFN interaction in vivo was tested
through combined treatment of C57BL/6 mice with ethanol and the 5-NFN,
NAZ in mice heterozygote and homozygote for theAldh1b1-null allele (Figure
3.19). Administration of NAZ at 150 mg/kg in presence or absense of 20%
ethanol and subsequent measurement of ALDH activity with
PicoProbe™assay did not reveal altered changes in overall liver ALDH
activity in ALDH1B1 deficient or proficient mice (Figure 3.20).
Figure 3.19: Experimental Protocol for Testing ALDH:5-NFN Interaction
In Vivo
C57BL/6 mice were administered 20% ethanol in drinking water
for 7 days, followed by co-treatment with 20% ethanol and NAZ
(150 mg/kg). After a total of 11 days, liver was harvested for
analysis of ALDH activity and circulating blood was harvested by
puncture of the inferior vena cava.
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Figure 3.20: Nifuroxazide Does Not Alter Overall Liver ALDH Activity In
Vivo Upon Measurement with the ALDH PicoProbe™ Assay
PCLS were prepared from the left lateral lobe of 6-8 week
C57BL/6 mice and incubated with NFN compounds at 5 µM and
10 µM concentration for 24 h before analysis of ALDH activity via
PicoProbe™assay (N = 3-5).
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3.2.9 The Effect of 5-Nitrofurans on Endogenous ALDH
Substrate Levels In Vivo
As an interaction between ALDH and 5-NFNs was observed in vitro and ex
vivo in liver, it was hypothesised that delivery of 5-NFNs in vivo would alter
metabolism of ALDH substrates in vivo. Moreover, it was speculated that
inhibition of ALDH activity would result in accumulation of the ALDH1B1 and
ALDH2 substrate, acetaldehyde. Acetaldehyde was focused on as a key
substrate to be altered by 5-NFN exposure because: (i) Acetaldehyde is a
common substrate for ALDH1B1 and ALDH2 enzymes and ALDH2 and
ALDH1B1 are the two principal enzymes involved in acetaldehyde
metabolism (ii) Patients treated with the 5-NFN, nifurtimox are intolerant to
ethanol and acetaldehyde is a major ethanol metabolic product. To establish
whether 5-NFNs perturb ALDH metabolic pathways in vivo, targeted analysis
of the primary ALDH2 and ALDH1B1 substrate and ethanol metabolic
product, acetaldehyde upon ethanol and 5-nitrofuran exposure was
investigated. C57BL/6 mice homozygote or heterozygote for the
acetaldehyde-metabolising enzyme, Aldh1b1 were exposed to nifuroxazide
and ethanol. After 11 days, at experimental end point, circulating blood
samples were harvested (Figure 3.21).
As acetaldehyde is the primary major substrate of ALDH, plasma levels of
acetaldehyde were measured using an ELISA-based assay. The
ELISA-based assay for determination of aldehyde levels entailed incubation
of 50 µL of freshly-harvested mouse plasma with a recombinant yeast ALDH
in the presence of NAD for 20 min. The amount of acetaldehyde in the
sample is indirectly determined by measuring the amount of NADH generated
during the reaction time from the recombinant ALDH. Acetaldehyde levels are
interpolated from an acetaldehyde ammonia trimer standard curve that was
incubated alongside the samples. Treatment of Aldh1b1-null heterozygous
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Figure 3.21: Experimental Protocol for Assessing the Downstream
Effects of the ALDH:5-NFN Interaction In Vivo
C57BL/6 mice were administered 20% ethanol in drinking water
for 7 days, followed by co-treatment with 20% ethanol and
nifuroxazide (150 mg/kg). After a total of 11 days, liver was
harvested for analysis of ALDH activity and circulating blood was
harvested by puncture of the inferior vena cava.
and homozygous mice with a co-administration of 20% ethanol and 150
mg/kg NAZ yielded elevated levels of circulating acetaldehyde (P = 0.0238)
(Figure 3.22).
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Figure 3.22: 5-Nitrofurans Alter Acetaldehyde Metabolism in ALDH1b1
Mutant Mice
Circulating blood was harvested at the experimental endpoint.
Levels of the ALDH substrate, acetaldehyde were quantified
through ELISA-based assay employing recombinant yeast ALDH
and readout of NADH generation. Treatment of ALDH1b1-null
mice with co-administrated ethanol and NAZ yielded elevated
levels of circulating acetaldehyde. Statistical significance was
tested by Mann-Whitney U test. Error bars represent standard
error of the mean (N = 3-5) (P = 0.0238).
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3.3 Summary
In this chapter the potential for ALDH:5-NFN interactions in mammalian
systems was explored. I identified that 5-nitrofurans inhibit the
dehydrogenase and esterase activity of ALDH enzymes toward aldehyde and
ester substrates. I demonstrated that ALDH1B1 and ALDH2 enzymes are
expressed in the liver at the transcript and protein level, are catalytically active
and remain expressed in the ex vivo precision cut liver slice model during
short-term culture. I utilised this tool to investigate the ALDH:5-NFN
interaction ex vivo and critically observed that inhibition of the dehydrogenase
activity of ALDHs by physiological levels of 5-NFNs is recapitulated in
ALDH-expressing tissue models and is potent enough to be revealed after
only 24 h of 5-NFN exposure. Not only did I find that the dehydrogenase
capacity of ALDH1B1 is altered by 5-NFN exposure but that the activity of
ALDH2 toward ester substrates is also inhibited in vitro. The inhibitory activity
of 5-NFNs against ALDH enzymes was not recapitulated when the
dehydrogenase activity of in vivo ALDH enzymes was tested by ELISA-based
ALDH assays after exposure to the 5-NFN, nifuroxazide. When I tested the
inhibitory effects of high concentrations of 5-NFNs toward ALDHs in vitro,
nifuroxazide was discovered to be the least potent inhibitor. A lower
concentration of nifuroxazide in vivo resulting from 150 mg/kg dose compared
to 10 µL ex vivo dose coupled to a relatively short half-life of nifuroxazide
might explain why these inhibitory effects were not seen in vivo. Potentially,
ethanol exposure in the ALDH1b1-null mice could have led to a compensatory
upregulation of the ALDH2 isoform that the in vivo dehydrogenase activity
assay would not delineate. Treatment of ALDH1b1 homozygous-null mice
with a combination of ethanol and nifuroxazide was sufficient to elevate
circulating concentrations of acetaldehyde in plasma. This indicates that
nifuroxazide and ethanol coexposure in mice that are deficient for one of the
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two major acetaldehyde-metabolising enzymes is a stressor to the
acetaldehyde detoxification pathway. In ALDH1b1 heterozygous mice,
expression of ALDH1B1 reduces the impact of nitrofuran and ethanol
coexposure on levels of acetaldehyde when compared to vehicle control,
emphasising the importance of ALDH1B1 as a 5-nitrofuran target and for
protection against 5-Nitrofuran-induced acetaldehyde accumulation.
Reassuringly, given the hepatotoxic side effects of 5-NFNs, I show that
5-nitrofurans are cytotoxic to HepG2 cells of liver origin. Given that ALDH1B1
and 2 are expressed in this cell line and were shown to inhibit ALDH activity in
vitro and ex vivo, I hypothesised that ALDH inhibition by 5-nitrofurans would
make cells more sensitive to exogenous exposure to the toxic ALDH
substrate, acetaldehyde. As there are fundamental differences in the three
most popular classes of synergy reference models: HSA (Berenbaum, 1989),
Loewe (Loewe, 1953) and Bliss (Bliss, 1939), data tested against all three
models were reported. One commonality between these three reference
models is that an assumption is made about the expected effect of two
components in a combination matrix not interacting (Yadav et al., 2015). The
HSA model takes the simple assumption that the expected effect of
combination is one that is equal to or greater than the effect seen when a
single drug is applied at a high concentration. From a synergy perspective,
this model assumes that the effect of the drug combination is more than the
sum of the effect of its parts. For example, that if a synergistic effect is
apparent, the response to a combination of acetaldehyde and ethanol is
greater than the sum of the response from a single administration of ethanol
or acetaldehyde. The Loewe model presents the most compelling data to
support a synergistic model of interaction between acetaldehyde and NFN1
and is reportedly a more stringent method of synergy modelling (Yadav et al.,
2015). Loewe is based on an additivity approach that predicts what the effect
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would be if a drug was combined with itself. The Bliss independence model is
also regarded as more stringent and models the effects of individual drugs in
a combination as independent yet competing events (Yadav et al., 2015).
5-NFN treatment enhanced the sensitivity of cells to the toxic effects of
exogenously administered acetaldehyde in a synergistic manner. The
synergistic effect between acetaldehyde and NFN1 is most notable at higher
concentrations of each component (Figure 3.18). Collectively, this data
supports a mechanism whereby exposure to 5-NFNs, particularly NFN1 and
nifuroxazide inactivates the core ALDH1B1 and ALDH2 catalytic activity of
enzymes expressed in the liver. I hypothesised that 5-NFNs would have the
potential to invoke changes to acetaldehyde metabolism and that this is
responsible for their in vivo toxicity. To address this, I quantified the levels of
circulating acetaldehyde in the plasma of Aldh1b1-null homozygous and
heterozygous mice upon nifuroxazide and ethanol exposure. In this
Aldh1b1-deficient model, Aldh2 is the only key acetaldehyde-metabolising
enzyme present. Upon ethanol challenge, acetaldehyde levels were not
significantly altered, which could be due to a compensatory upregulation of
Aldh enzyme in response to ethanol and therefore acetaldehyde exposure. In
mice homozygous for the Aldh1b1-null allele, nifuroxazide and ethanol
co-exposure resulted in significantly increased levels of circulating plasma
acetaldehyde. These results provide evidence that 5-nitrofurans inactivate
ALDH1B1 and ALDH2 catalytic activity in the liver and that this has a
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4.1 Introduction
4.1.1 Overview
Various methods can be used to evaluate the presence of aldehydes in
biological systems. These include the use of flurorescent probes, enzyme
assays and MS-based detection and quantification. In the previous chapter, I
evaluated the relative abundance of acetaldehyde through use of an
ELISA-based method. Whilst this method allows comparison of relative
acetaldehyde amounts between samples, HPLC and MS-based techniques
offer the opportunity to quantify absolute levels of aldehydes in biological
matrices. Despite research toward understanding ALDH networks and the
function of ALDH in aldehyde metabolism, 19 human isoforms of ALDH have
been classified and the full repertoire of aldehydes that are metabolised by
these enzymes has not yet been established. I chose to set up a workflow
that would enable detection and quantification of acetaldehyde in plasma that
could be readily adapted for the analysis of other aldehydes with a similar
experimental approach in the future.
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4.1.2 Aims
This second results chapter encompasses the aim to develop a method of
aldehyde quantification that would enable high throughput analysis of
aldehydes in low-volume plasma samples. To this end, the experiments in this
chapter were performed under the following objective:
1. Establish an analytical method for aldehyde measurement in plasma
samples.
To achieve this objective, an experimental approach was developed
whereby aldehydes were rapidly derivatised to ensure their minimal loss
from samples, followed by chromatographic separation and
MS-detection of derivatised aldehydes using Triple-Quadrupole-MS/MS
and High-Resolution Accurate-Mass (Orbitrap) MS techniques.
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4.2 Results
4.2.1 HPLC-MS Based Detection of Aldehydes
With the aim of establishing an LC-MS method for the analysis of derivatised
acetaldehyde and other aldehyde ALDH1B1/2 substrates in plasma, the
following stages of method development were performed:
1. Chromatographic separation of acetaldehyde-2,4-DNPH was optimised
with different stationary and mobile phases.
2. Detection of parent ions for acetaldehyde-2,4-DNPH was achieved. This
was performed on two systems:
(i) UltiMate™3000 HPLC (Thermo) inline with the Q Exactive™Orbitrap
system (Thermo)
(ii) Acquity™Ultra Performance LC (Waters) inline with a QTrap 5500 (AB
Sciex).
3. Derivatisation of acetaldehyde and deuterated acetaldehyde internal
standard, d4-acetaldehyde with 2,4-DNPH.
4. Product ions for acetaldehyde-2,4-DNPH and
d4-acetaldehyde-2,4-DNPH were generated and transitions selected for
quantitation.
5. Standard curve was established for acetaldehyde-2,4-DNPH in aqueous
solution.
6. Clean-up of derivatisations in aqueous and plasma matrix was tested.
7. Standard curve was established for acetaldehyde-2,4-DNPH in plasma
matrix.
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4.2.2 Orbitrap, High Resolution Accurate-Mass HPLC-MS
Detection
4.2.2.1 Chromatographic Separation of Aldehyde-2,4-DNPHs in Water
and Plasma Matrices
For concentration and targeted selection of acetaldehyde-2,4-DNPH, HPLC
conditions were established using pre-synthesised aldehyde-2,4-DNPH
reference standards. Carbon-18 was selected as a suitable stationary phase
and the gradient in Table 4.1 was found to afford separation of
aldehyde-2,4-dinitrophenylhydrazones using water and acetonitrile as the
mobile phases.
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Table 4.1: Chromatographic Gradient on Accucore™
C18
Retention (min) Flow (mL/min) % A % B Curve
0 0.05 98 2 5
0 0.3 80 20 5
0.3 0.3 80 20 5
0.5 0.3 80 20 5
4 0.3 70 30 5
7 0.3 10 90 5
9.5 0.3 10 90 5
10 0.3 80 20 5
12 0.3 80 20 5
12.1 0.02 80 20 5
Mobile Phase A, MS-grade water; Mobile Phase B,
acetonitrile.
Gradient flow rate, 0.3 mL/min.
Column temp, 45°C.
Column Type, Accucore™ C18 LC Column 80Å, 2.6 µm, 2.1
mm X 30 mm.
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Chromatograms of each aldehyde-2,4-dinitrophenylhydrazone were
compared between simple and more complex biological mixtures, water and
deproteinated plasma, respectively. Freshly collected mouse plasma and
MS-grade water was spiked with acetaldehyde-2,4-dinitrophenylhydrazone to
a final concentration of 10 µM (10% acetonitrile). Samples were
deproteinated through addition of 1 volume acetonitrile and 2.5 volumes
methanol. Supernatant was vacuum concentrated and resulting pellets were
resuspended to initial volume in 2% acetonitrile before chromatographic
analysis on Accucore™C18 HPLC column, injecting 20 µL volume (44.8 ng
on column mass of acetaldehyde-2,4-DNPH). Peaks were selected for each
aldehyde-2,4-dinitrophenylhydrazone (Figure 4.1A, Figure 4.2A, Figure 4.3A).
Peak intensity was calculated for water and plasma-spiked samples (Figure
4.1B, Figure 4.2B, Figure 4.3B). These conditions enabled HPLC-MS
detection of the parent ion of each aldehyde-2,4-dinitrophenylhydrazone. For
these reasons, this chromatography set-up was chosen as the buffer system
going forwards.
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Figure 4.1: HPLC-MS Analysis of Plasma and Water Matrices Fortified
with Acetaldehyde-2,4-DNPH Standard
2% acetonitrile loading conditions. Data points are the mean of 3
technical replicates. Error bars represent standard deviation.
Statistical significance was tested by ANOVA.
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Figure 4.2: HPLC-MS Analysis of Plasma and Water Matrices Fortified
with Formaldehyde-2,4-DNPH Standard
2% acetonitrile loading conditions. Data points are the mean of 3
technical replicates. Error bars represent standard deviation.
Statistical significance was tested by ANOVA.
145 Chapter 4
Aldehydes, gene-drug interactions and cancer subpopulations
Figure 4.3: HPLC-MS Analysis of Plasma and Water Matrices Fortified
with Propionaldehyde-2,4-DNPH Standard
2% acetonitrile loading conditions. Data points are the mean of 3
technical replicates. Error bars represent standard deviation.
Statistical significance was tested by ANOVA.
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4.2.3 Fortification of Plasma with Aldehyde-DNPH
Standards Yields Quantifiable Increases in
Corresponding Peak Intensity
Mouse plasma, 90 µL was spiked with serially diluted
aldehyde-2,4-dinitrophenylhydrazones to final concentrations in the range 1
nM to 10 µM (10% acetonitrile). Samples, 100 µL were deproteinated through
addition of 1 volume acetonitrile and 2.5 volumes methanol. Supernatant was
vacuum concentrated and resulting pellets were resuspended to the initial
plasma volume in 2% acetonitrile before chromatographic analysis on
Accucore™ C18 HPLC column. The parent ion of each
aldehyde-2,4-dinitrophenylhydrazone was monitored, eluting peaks were
selected for each aldehyde-2,4-dinitrophenylhydrazone and peak area
intensity quantified using AssayR (Figure 4.4, Figure 4.5, Figure 4.6).
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Figure 4.4: HPLC-MS Analysis of Plasma Matrix Fortified with
Acetaldehyde-2,4-DNPH Standard (1 nM - 10 µM)
Acetaldehyde-2,4-DNPH standards were spiked into 90 µL of
plasma at a final concentration of 1 nM - 10 µM. Final loading
conditions were in 2% (v/v ) acetonitrile.
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Figure 4.5: HPLC-MS Analysis of Plasma Matrix Fortified with
Formaldehyde-2,4-DNPH Standard (1 nM - 10 µM)
2% acetonitrile loading conditions. Formaldehyde-2,4-DNPH
standards were spiked into 90 µL of plasma at a final
concentration of 1 nM - 10 µM. Final loading conditions were in
2% (v/v ) acetonitrile.
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Figure 4.6: HPLC-MS Analysis of Plasma Matrix Fortified with
Propionaldehyde-2,4-DNPH Standard (1 nM - 10 µM)
Propionaldehyde-2,4-DNPH standards were spiked into 90 µL of
plasma at a final concentration of 1 nM - 10 µM. Final loading
conditions were in 2% (v/v ) acetonitrile.
150 Chapter 4
Aldehydes, gene-drug interactions and cancer subpopulations
Serial dilutions of each aldehyde-2,4-dinitrophenylhydrazone yielded
corresponding changes in peak intensity. To observe whether standards were
binding to the column between runs due to incomplete elution of adsorbed
molecules or whether reference standards contained trace amounts of
additional contaminating aldehyde, parent ions for all three
aldehyde-2,4-DNPH were examined in each standard, scanning the three
parent ions; acetaldehyde-2,4-DNPH, m/z 223.0473;
propionaldehyde,2,4-DNPH, m/z 237.0629; formaldehyde-2,4-DNPH, m/z
209.0316 (Figure 4.7). Reassuringly, for each aldehyde-2,4-DNPH the
highest intensity peak identified was for the parent ion of that molecule and
peak intensities increased relative to analyte concentration. Next, lower
concentrations of acetaldehyde-2,4-DNPH were tested on a replacement C18
column; increasing concentration of acetaldehyde-2,4-DNPH standard was
correlated with relative increases in peak intensity of the parent ion,
acetaldehyde-2,4-DNPH m/z 223.0473 (Figure 4.8).
151 Chapter 4






















































































































































































































































































































































































Aldehydes, gene-drug interactions and cancer subpopulations
Figure 4.8: HPLC-MS analysis of Plasma Fortified with
Acetaldehyde-2,4-DNPH
(2% acetonitrile loading conditions)
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4.2.4 Triple-Quadrupole MS Based Detection
4.2.4.1 Chromatographic Detection of Acetaldehyde-2,4-DNPHs
Next, acetaldehyde-2,4-DNPH standard was analysed on a Triple-quadrupole
system. It is standard for quantitative MS to be performed on a
Triple-quadrupole due to their sensitivity and robustness. This is in contrast to
discovery, where high-resolution accurate-mass Orbitrap mass spectrometers
excel.
4.2.4.2 Tuning on Reference Standard and Synthesised Aldehyde-DNPH
Standards
Identification of parent ion for reference standard
To verify the molecular weight of the reference standard for
acetaldehyde-2,4-DNPH, a Q1 (survey) scan was performed on 10 ng/mL (45
nM) standard directly injected to the MS and analysed in negative mode
(Figure 4.9A). Acetaldehyde-2,4-DNPH is displayed in the mass spectrum,
m/z 223.2. The [M-H]- peak verified presence of the parent ion. Expansion of
the m/z axis range to m/z 222.5-223.9 highlighted the peak apex of the parent
ion at m/z 223.1 (Figure 4.9B).
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Figure 4.9: Tuning on Acetaldehyde-2,4-DNPH Standard
The acetaldehyde-2,4-DNPH reference standard was directly
infused to the MS at a concentration of 10 ng/mL (45 nM) in H2O.
A. Full-scan mass chromatogram (m/z 50-400 amu) of
acetaldehyde-2,4-DNPH. B. The [M-H]- parent ion of
acetaldehyde-2,4-DNPH observed at m/z 223.1. Axis range m/z
222.5 - 223.9.
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Identification of product ions for pre-synthesised reference standard
The top four product ions from [M-H]- parent ion m/z 223.1 that were identified
during tuning are listed in Table 4.2.
Table 4.2: Product Ions from
Acetaldehyde-2,4-DNPH Standard [M-H]-
(precursor ion m/z 223.1
product ion m/z CE (V ) CXP (V ) intensity
1 151.00 -14 -13 62480
2 163.10 -16 -7 54120
3 121.9 -26 -11 52480
4 76.0 -20 -7 47060
collision energy (CE); cell exit potential (CXP).
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4.2.5 Aldehyde Derivatisation
In the previous method development steps, optimisation of sample loading
conditions and chromatography was performed with aldehyde-2,4-DNPH
reference standards. This enabled:
1. establishing a diagnostic ion for each aldehyde derivative.
2. elucidation of optimal HPLC conditions for the derivatives of interest.
Because this method was to be applied to biological samples of blood
origin and derivatisation was chosen to improve acetaldehyde detection, the
acetaldehyde derivatisation reaction was performed in aldehyde-spiked
plasma. This was important for method development because it enables:
1. establishment of the efficiency of derivatisation
2. optimisation of factors controlling the efficiency of derivatisation;
temperature, pH, concentration of DNPH.
3. determination of the minimal and maximum limits of detection of aldehyde
in plasma matrix.
Ultimately, initiating these method development studies into acetaldehyde
derivatisation paves the way for derivatisation of aldehydes in the blood of mice,
and specifically, the quantification of aldehydes including acetaldehyde-DNPH
with high-resolution accurate-mass LC-MS.
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4.2.5.1 Derivatisation of Aldehydes in Water and Plasma Matrices
Fortified with Aldehydes
Firstly, the derivatisation reaction of aldehydes with DNPH was tested.
Plasma was used as this was the intended sample matrix for acetaldehyde
quantification. Water samples spiked with aldehyde were also derivatised in
parallel, as a less complex control to address whether anything in the more
complex biochemical matrix of deproteinated plasma interfered with the
derivatisation reaction and consequent HPLC-MS analysis.
4.2.5.2 UV-Vis Detection of Aldehyde-2,4-DNPH Compounds
To test the success of the derivatisation reaction and address whether
aldehyde derivatives were synthesised under the tested conditions, the
absorbance of samples at 430 nm was monitored by UV-Vis. To test the
suitability of this as an indicator of successful derivatisation, absorbance of
serially diluted pre-synthesised acetaldehyde-2,4-DNPH reference standard
was measured (Figure 4.10A). Standards were solubilised in acetonitrile but
acetonitrile absorbs at a similar wavelength to the aldehyde-2,4-DNPH
compounds. A solution to this was to incubate the aldehyde-2,4-DNPH
compounds in alkaline conditions by addition of 2M NaOH to the reference
standard or reaction mixture. Under alkaline conditions, the absorbance of
racetaldehyde-2,4-DNPH reference standard shifted (Figure 4.10A).
Increasing concentrations of acetaldehyde-2,4-DNPH were accompanied by
relative increases in peak intensity at 430 nm (Figure 4.10B,C). Monitoring the
absorbance of acetaldehyde-2,4-DNPH under alkaline conditions at 430 nm
could therefore afford confirmation of its presence in derivatised standards
and samples and would be utilised to address sample extraction efficiency
with solid phase extraction methods.
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Figure 4.10: UV-Vis Detection of Acetaldehyde-2,4-DNPH
Reference standards solubilised in 100% acetonitrile (MeCN).
A. Absorbance Spectra of acetaldehyde-2,4-DNPH (350-600
nm). B. Increasing concentrations of acetaldehyde-2,4-DNPH
were accompanied by relative increases in peak intensity at 430
nm. C. Standard curve, Concentration of
acetaldehyde-2,4-DNPH against absorbance at 430 nm (λ= 430
nm).
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4.2.5.3 Extraction of Derivatised Aldehydes
Extraction method
Following the derivatisation reaction, the reaction mixture contained high salt
concentrations that are incompatible with MS systems. Although it is possible
to divert salt away from the Orbitrap source during loading onto the HPLC, solid
phase extraction (SPE) was employed to separate the reaction product from the
high-salt reaction mixture (Figure 4.11).
Figure 4.11: Workflow for Solid Phase Extraction of Derivatised
Aldehyde-2,4-DNPHs
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Extraction of acetaldehyde-2,4-DNPH
To test the suitability of SPE for reaction clean-up, reference standards were
subjected to clean-up on StageTips containing C18 disks (Rappsilber et al.,
2007). Standards were solubilised in different concentrations of acetonitrile
(2% and 20%) to determine optimal binding conditions for the standards.
Reference standards in both 2% and 20% acetonitrile exhibited good binding
to the column and eluted well with 35% acetonitrile (Figure 4.12). The UV-Vis
absorbance for reference aldehyde derivative standards was higher for
samples dissolved in 20% acetonitrile than 2% acetonitrile. The difference in
absorbance could be a result of better solubility and dissolution of aldehyde
derivative reference standards in 20% acetonitrile than 2% acetonitrile.
Deproteinated samples containing 1 mM acetaldehyde were derivatised in
80-fold molar excess DNPH and formation of the product monitored with
UV-Vis (Figure 4.13).
Figure 4.12: Solid Phase Extraction of 1 mM acetaldehyde-2,4-DNPH
Solution with StageTips
Reference standards solubilised in 2% and 20% acetonitrile
(MeCN) were subjected to SPE on C18.
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Figure 4.13: Solid Phase Extraction of Derivatised Acetaldehyde with
StageTips
1 mM acetaldehyde was derivatised with 80-fold molar excess
DNPH, reaction products were cleaned-up with SPE on C18
material and resulting product alongside reference standard was
solubilised in 20% acetonitrile. Absorbance at 420 nm was
assayed under alkaline conditions (2M NaOH, 50 µL: reaction
product 50 µL).
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4.2.5.4 Identification of Parent Ion for Synthesised Standard
To verify the molecular weight of the freshly synthesised
acetaldehyde-2,4-DNPH standard, a Q1 (survey) scan was performed on
infused standard using a QTrap 5500 mass spectrometer, operated in
negative ion electrospray ionisation (ESI) mode. Acetaldehyde-2,4-DNPH
was diluted in mobile phase (water:acetonitrile 4:1, v/v ).
Acetaldehyde-2,4-DNPH is displayed in the mass spectrum at m/z 223.1
(Figure 4.14). The presence of the [M-H]- peak verified the presence of the
parent ion as a reporter of the presence of acetaldehyde-2,4-DNPH.
Figure 4.14: Tuning On Derivatised Acetaldehyde-2,4-DNPH Standard
Derivatised acetaldehyde-2,4-DNPH was directly injected to the
MS at a dilution of 1:1000000 in 100% acetonitrile. Full survey
scan was performed (m/z 50.0-400.0).
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4.2.5.5 Identification of Product Ions for Derivatised Acetaldehyde-2,4-
DNPH
Acetaldehyde was derivatised through 1:1 (v/v ) reaction with DNPH solublised
in HCL and the reaction proceeded for 1 h at room temperature. The resulting
reaction was diluted 1:10000 in H2O and infused to isolate the [M-H]- parent
ion of acetaldehyde-2,4-DNPH. The [M-H]- ion with m/z 223.1 was observed
during full survey scan in the m/z range 50.0 - 400.0. The top four transitions
from the [M-H]- parent ion m/z 223.1 identified during tuning are listed in Table
4.5.
Table 4.3: Product Ions from Derivatised
Acetaldehyde-2,4-DNPH (precursor ion
m/z 223.1)
product ion m/z CE (V ) CXP (V ) intensity
1 151.0 -14 -13 82680
2 122.0 -28 -11 70070
3 59.1 -26 -7 63860
4 76.0 -18 -7 49990
collision energy (CE); cell exit potential (CXP).
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4.2.5.6 Tuning on d4-Labelled Derivatised Acetaldehyde
4.2.5.7 Derivatisation
To evaluate the efficiency and success of derivatisation, it is imperative that
derivatisation of an internal standard that is chemically distinct from the
analyte of interest is performed. Deuterated acetaldehyde (d4-acetaldehyde)
was chosen as an appropriate internal standard and was subsequently
derivatised. Reassuringly the [M-H]- ion, m/z = 227.1 was observed after
direct injection of the reaction. Tuning of this for the top four product ions of
the [M-H]- ion is presented in Table 4.4.
Table 4.4: Product Ions from Derivatised
d4-Acetaldehyde-2,4-DNPH (precursor
ion m/z 227.1)
product ion m/z CE (V ) CXP (V ) intensity
1 167.0 -16 17 57100
2 137.0 -26 -15 21430
3 76.0 -20 -7 16210
4 123.0 -28 -9 15640
collision energy (CE); cell exit potential (CXP).
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4.2.5.8 Standard Curve: Derivatised Standard
Acetaldehyde was spiked into plasma to a final concentration of 2 mg/mL,
derivatised with DNPH in 6N HCL and serially diluted. Ten microlitres of 40, 5
and 2.5 ng/mL solutions were injected onto C18 (400, 50 and 25 pg on
column masses, respectively) (Table 4.5). Chromatographic separation of
acetaldehyde-2,4-DNPH was monitored with the m/z 223>122 transition
(Figure 4.15A). Plotting of analyte relative concentration (2.5-40 ng/mL, ≈
10-180 nM) against peak area counts for the transition m/z 223>122 to
generate a standard curve demonstrated a linear relationship between
concentration and peak intensity (Figure 4.15B).
Table 4.5: Detection of Acetaldehyde-2,4-DNPH Transition m/z 223>122 in
Plasma Spiked with Acetaldehyde and Derivatised with DNPH
run type DNPH peak area [acetaldehyde] retention time (min)
order (ng/mL)
1 solvent blank 2480 0.00 3.49
2 double blank 25000 0.00 3.49
3 standard 3 46800 0.00 3.49
4 standard 3 61400 2.50 3.48
5 standard 3 76400 5.00 3.48
6 standard 3 376000 40.0 3.47
7 solvent blank 517 0.00 3.47
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Figure 4.15: Standard Curve for Derivatised Acetaldehyde-2,4-DNPH
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4.2.5.9 Derivatisation of Acetaldehyde and d4-Acetaldehyde
Derivatisation
Next, derivatisation of acetaldehyde alongside a deuterated isotope was
performed. Both acetaldehyde and the deuterated isotope, d4-acetaldehyde
(internal standard) at equal concentrations of 4 mg/mL were derivatised in a
1:1 (v/v ) reaction with 20 mg/mL DNPH in 6N HCL at RT for 1 h at a final
reaction volume of 200 µL.
Chromatography and MS Detection
The resulting reaction mixture was diluted 1:10000 in H2O to reduce the peak
intensity and was separated using column and gradient settings indicated in
Table 4.6. Tuning conditions that were used for analysis of the
acetaldehyde-2,4-DNPH and d4-acetaldehyde-2,4-DNPH in these samples
are displayed in Table 4.7. Samples, 10 µL were injected and Multiple
Reaction Monitoring (MRM) for transitions of derivatised acetaldehyde (m/z
223.0>59.1, 223.0>76.0, 223.0>151.0, 223.0>122.0) and derivatised
d4-acetaldehyde (m/z 227.1>76.0, m/z227.1>123.0, m/z227.1>137.0,
m/z227.1>167.0) was used to detect the derivatised aldehydes (Figure 4.16,
Figure 4.17).
Derivatised acetaldehyde and d4-acetaldehyde were analysed for the
tuned transitions that correspond to acetaldehyde-2,4-DNPH (m/z 223.0)
(Table 4.7, Figure 4.16). The resulting chromatograms indicate peaks for
each ion transition, confirming their use as quantitative ions. Reassuringly, no
peaks were observed in samples containing d4-acetaldehyde and no
acetaldehyde. Transition m/z 223.0>76.0 was chosen as the major
quantitative ion to be taken forwards due to its high peak intensity and
distinctive peak. When the same derivatised samples were analysed for the
presence of the tuned transitions for d4-acetaldehyde-2,4-DNPH (m/z227.1)
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(Table 4.7, Figure 4.17), the transition m/z 227.1>76.0 was selected as this
exhibited a high-intensity peak with no signs of ion suppression as with the
other transitions, m/z 227.1>167.0 and m/z 227.1>137.0. Reassuringly,
peaks for the transition m/z 227.1>76.0 that correspond to
d4-acetaldehyde-2,4-DNPH were not present in the acetaldehyde-only
containing samples and were at minimal (≈ 300) intensity in the mobile phase
blank.
Table 4.6: Chromatographic Gradient on ACQUITY
C18
Retention (min) Flow (mL/min) %A %B Curve
1.5 0.4 75 15 5
2.00 0.4 15 85 5
5.00 0.4 15 85 5
5.50 0.4 85 15 5
7.50 0.4 85 15 5
Buffer A, MS-grade water; Buffer B, acetonitrile.
Gradient flow rate = 0.4 mL/min
Column temp = 45°C
Column Type = Waters ACQUITY UPLC HSS T3 Column,
100Å, 1.8 µm, 2.1 mm X 150 mm.
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4.2.5.10 Acetaldehyde-2,4-DNPH Standard Curve
To test the derivatisation of different concentrations of acetaldehyde, 100 µL
serial dilutions of acetaldehyde starting at 4 mg/mL alongside 100 µL of 4
mg/mL internal standard, d4-acetaldehyde were derivatised with 100 µL of 20
mg/mL DNPH in 6N HCL at room temperature for 1 h in a total reaction
volume of 300 µL. Reactions were diluted 1:10000 in H2O to a final volume of
200 µL and 10 µL injected on column, resulting in an on-column mass of 13
ng - 65 pg derivatised aldehyde and 13 ng mass of derivatised
d4-acetaldehyde analysed. Detection of the ion transitions m/z 223>76, m/z
227>76 (Figure 4.18) were used to generate a standard curve (Table 4.8,
Figure 4.19).
Figure 4.18: Extracted Ion Chromatogram for Ion Transitions of
Acetaldehyde-2,4-DNPH and d4-Acetaldehyde-2,4-DNPH
Extracted Ion Chromatogram for m/z 227>76 transition of
d4-acetaldehyde-2,4-DNPH.
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Figure 4.19: Standard Curve for Transition m/z 227>m/z 76 of Derivatised
Acetaldehyde
Standard curve generated from normalised Peak Area of
derivatised acetaldehyde and d4-acetaldehyde. Transition m/z
227>m/z 76.
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4.2.5.11 Effect of pH on Aldehyde Derivatisation
The composition of solvents used to solubilise DNPH were tested for their
effect on aldehyde derivatisation. D4-acetaldehyde was serially diluted and




(iii) acetonitrile:0.001N HCl (aq) (3:2 v/v ), pH 3
(iv) acetonitrile:water (3:2 v/v ), pH 6
The reaction, 300 µL was diluted 1:10000 in H2O and 10 µL was injected onto
column (Figure 4.20). Resulting chromatographs indicate that both 6N HCL
and acetonitrile:0.001N HCl (aq) (3:2 v/v ), pH 3 afforded efficient
derivatisation and detection of d4-acetaldehyde.
176 Chapter 4
Aldehydes, gene-drug interactions and cancer subpopulations
Figure 4.20: Derivatisation of d4-Acetaldehyde with varying pH
Peak intensity of the m/z 227.100>76.000 transition was
measured in samples derivatised with DNPH in 6N HCL; 0.1N
HCL; 60% acetonitrile : 40% 0.001 N HCL, pH 3; or 60%
acetonitrile : 40% water, pH 6.
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4.3 Summary
This chapter initiated method development for the derivatisation and
HPLC-MS analysis of aldehydes in plasma. To increase throughput and
enable detection of multiple aldehydes in plasma matrices, improving on the
selectivity of ELISA-based methods for acetaldehyde detection, a sample
preparation and HPLC-MS method to derivatise and detect acetaldehyde in
blood plasma was set up. Derivatisation with DNPH was employed to
generate aldehyde-2,4-DNPHs with enhanced stability and molecular weight
for HPLC-MS detection. I explored a broader approach to aldehyde
quantitation with Orbitrap LC-MS that opened up potential to explore the
metabolism of multiple aldehydes during a single MS run. This enabled me to
follow three aldehydes during chromatographic set up and paired with the
derivatisation approach, yields opportunity to address aldehyde biology in a
broader context, focusing on quantification of several aldehydes in a
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Expression Network in Melanoma
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5.1 Introduction
5.1.1 Overview
ALDH enzymes are experimental markers of cell populations with
cancer-initiating ability and development of chemoresistance. Although ALDH
activity is widely reported as a marker of these properties, it is clear that
ALDH has a functional role in establishing cancer-initiation and development
of chemoresistance. For example, subpopulations of ALDH1A3high cells have
been identified in melanoma (Boonyaratanakornkit et al., 2010; Luo et al.,
2012), ALDH1A3 is upregulated in melanoma cells when compared to
melanocytes (Pérez-Alea et al., 2017) and is also upregulated following
treatment of melanoma with BRAF and MEK inhibitors (Sarvi et al., 2018).
Considering that ALDH1A3 levels are elevated during tumorigenesis and
upon development of resistance to current targeted chemotherapeutics,
ALDH1A3 is an attractive candidate for the development of targeted inhibitors.
The 5-nitrofuran, nifuroxazide is an inhibitor of ALDH1A3 enzymatic
activity in vitro and exposure of the A375 melanoma cell line to nifuroxazide or
DIMATE selectively depletes cells that express high levels of ALDH
(ALDH1A3high), as demonstrated by ALDEFLUOR™ staining (Sarvi et al.,
2018; Pérez-Alea et al., 2017). Although ALDH1A3 is an appealing target for
the development of chemotherapeutics, the functional advantage to cells of
ALDH1A3-expression in chemoresistance has not been determined.
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5.1.2 Aims
The Patton laboratory has previously demonstrated that ALDH1A3 is targeted
by nifuroxazide in melanoma, selectively targeting ALDH1A3high melanoma
populations. I hypothesised that the ALDH1A3high population would possess a
gene expression profile distinct from ALDH1A3low and ALDH1A3null
populations and that gene expression would be dependent upon retinoic acid
signalling. This results chapter explores the aim to understand the
consequence of ALDH1A3 expression on cellular transcriptional profiles. To
this end, the experiments in this chapter were performed under two objectives:
1. Identify key transcriptional programmes of ALDH1A3high, ALDH1A3low
and ALDH1A3null populations
To achieve this objective, A375 melanoma cells were isolated on the
basis of their ALDH-expression. ALDH1A3high and ALDH1A3low cells
were analysed for transcriptional expression alongside an A375 cell line
null for ALDH1A3, A375-ALDH1A3C21.
2. Identify genes and transcriptional signatures that are dependent upon
ALDH1A3 activity to (i) decipher the differences between
Aldefluor™-sorted and ALDH1A3-null populations and (ii) establish
whether ALDH1A3 expression is essential for retinaldehyde and retinoic
acid transcriptional signalling in BRAFV600E melanoma.
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5.2 Results
5.2.1 Preparation of ALDH Subpopulations for mRNA-Seq
To characterise functional advantages of ALDH1A3 expression in melanoma
subpopulations, first I wanted to determine differences in the genetic
landscape of ALDH1A3 high and ALDH1A3 low expressing cells. To do this, I
analysed the ALDH-expression of A375 melanoma lines (Figure 5.1A) with
the ALDEFLUOR™ assay and sorted the top and bottom 5% of cells with
ALDH activity using flow cytometry.(Figure 5.1B). Upon flow cytometry
analysis of the A375 population, a strong ALDEFLUOR™ signal was
revealed, with successful inhibition of ALDEFLUOR™-staining in the
ALDEFLUOR™- and DEAB (ALDH inhibitor)- treated control. Ablation of
ALDH1A3 activity in ALDH1A3C21 resulted in a characteristic shift in
ALDEFLUOR activity that has been previously reported (Sarvi et al., 2018).
Total RNA was extracted from the sorted cell populations and prepared for
RNA sequencing (Figure 5.1B).
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Figure 5.1: A375 CRISPR Cell Lines
A. Human melanoma (A375) cell lines, ALDH1A3-Cas9 and
ALDH1A3-null CRISPR clone, A375-ALDH1A3C21.
B. A375-Cas9 cell line stained with ALDEFLUOR™ with or
without cotreatment with the ALDH inhibitor, DEAB. The top and
bottom 5% of ALDEFLUOR™-stained cells were cell sorted.
Messenger RNA was extracted from the top and bottom 5% and
an unsorted sample control sequenced.
C. The A375-ALDH1A3C21 CRISPR clone has minimal uptake of
ALDEFLUOR™ reagent. ALDEFLUOR™ staining of the
ALDH1A3-null cellular population overlaps with DEAB-treated
controls. Abbreviations; DEAB, N,N-diethylaminobenzaldehyde;
AF, ALDEFLUOR™.
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5.2.2 ALDHhigh and ALDHlow Populations Exhibit Different
Gene Expression Patterns
Once total mRNA NextSeq 550 sequencing was performed, reads were
aligned to the genome and processed normalised counts were processed
through analysis of differentially expressed genes (DEG) (Chapter 2). The
DEG list was sorted according to p-value and false discovery rate (FDR)
adjusted p-value (padj, q), using a 5% cut off threshold for each. Using both
the p-value and adjusted p-value (padj, q), a total of 2,236 genes of the
57,914 total mapped RNAs had expression values that were statistically
significant. These thresholds were applied because when measuring gene
expression levels of thousands of genes in a small sample set (N=3), the q
value takes into account the FDR and adds another level of stringency to the
analyses. Resulting differentially expressed genes in the ALDHhigh and
ALDHlow populations are represented with a volcano plot (Figure 5.2). Gene
plots highlighted in green represent those genes that are more highly
expressed in ALDH1A3high populations than ALDH1A3low. Grey plots highlight
genes that are more highly expressed in ALDH1A3low populations than
ALDH1A3high. Gene labels indicate the most differentially expressed genes
when using a highly stringent P value cut off below 1E-23.
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Figure 5.2: Differential Expression Analysis of ALDH1A3high and
ALDH1A3low Cells
Volcano plot representation of DEG analysis. Gene plots
highlighted in green represent those genes that are more highly
expressed in ALDH1A3high populations than ALDH1A3low. Grey
plots highlight genes more highly expressed in ALDH1A3low
populations than ALDH1A3high. Gene labels indicate the most
differentially expressed genes that have an adjusted P value <
1E-23. Non significant genes are labelled in black and have
P>0.05.
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5.2.3 ALDHhigh and ALDHlow Populations Express
Contrasting Networks of Genes
To investigate differential expression of pathways relevant in melanoma
between ALDH1A3high and ALDH1A3low cells, performed gene set enrichment
analysis (GSEA) was performed using gene lists that were curated from the
literature and cancer genome databases, including The Cancer Genome Atlas
(TCGA). This analysis revealed which pathways are differentially expressed in
melanoma cells that exhibit high and low levels of ALDH activity. Eight out of
twenty two gene sets passed thresholding (Figure 5.3). Given that these gene
sets covered a wide range of cancer specific pathways, it was interesting to
observe that clusters especially associated with MITF low expression (MITFlow
neurodevelopmental, development) and neural development (Rambow-NCSC
Cluster, WIKIP Neural Crest Differentiation). Not only were these neural gene
sets enriched in the ALDH high population, but complementary gene sets
including GO: Peripheral Nervous System Development and GO: Glial Cell
Differentiation gene sets were discovered in the top 10 differentially
expressed gene sets when Gene Ontology (GO) Analysis was performed.
The Microphthalmia-associated transcription factor, MITF is a determining
factor in melanocyte development and has been shown to be regulated by
SOX10 which binds at the Mitf promoter to activate transcription (Goding,
2000). Expression of Mitf is essential for the commitment to the melanocyte
lineage from neural crest precurors during development (Goding, 2000).
MITF-low cells have elevated motile and invasive capacity, have a higher
tumour-formation capacity in xenograft assays and arise spontaneously in
MITF-high cell cultures (Cheli et al., 2011). Further analysis of MITF target
genes in high and low ALDH populations revealed differential expression of
SLC16A6, MCOLN3, PSCA, CDKN2A, BCAN and ABCC2. The A375 cell line
is MITF -low and is resistant to MITF silencing (Wang et al., 2018),
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never-the-less, MITF targets are differentially expressed between ALDHhigh
and ALDH low cells.
With a focus on genes involved during neural crest and melanocyte
differentiation, GAS7 was a promising candidate for follow up from differential
expression of ALDH-high and ALDH-low cells 5.2. Although GAS7 is not
prognostic in melanoma (Human Protein Atlas), GAS7 is a key gene
described by Rambow et al. (2018) is a key set of neural crest stem cell
(NCSC) genes that comprise a deterministic signature for minimal residual
disease. Minimal residual disease describes the cells which remain during
chemotherapy and which eventually lead to tumour relapse. Analysis of this
NCSC signature (Figure 5.5) revealed a stark contrast between ALDH high
and low populations. Twenty one NCSC-determinant genes were expressed
at higher levels in ALDH high cells (Figure 5.5). This is a critical finding that is
highly relevant to uncovering the function of ALDH1A3 in the ALDH high,
tumour-initiating and chemo-resistant population.
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Figure 5.3: GSEA of Melanoma-Specific Transriptional Pathways
Gene enrichment plots highlight pathways that are statistically
differentially expressed between high and low ALDH-expressing
melanoma. The table (below) reports gene set against the size of
the gene set, normalised enrichment score (NES) and FDR
q-value. Statistically enriched gene sets were stringently refined
by using a FDR cut-off less than 0.01.
188 Chapter 5


































































































































































































































































































































































































































































Aldehydes, gene-drug interactions and cancer subpopulations
As the NCSC gene signature was highly expressed in the high
ALDH-expressing population, analysis was focused to the expression of
neural-associated genes and role of ALDH1A3 in governing the expression of
these. This was decided as retinoic acid is generated by the activity of
ALDH1A3 and is also heavily involved in the regulation of neural
development. With this in mind, I explored the expression of RXR and RAR
retinoic acid receptors in the ALDH high and low populations. RXRG was one
of the most abundant genes in the ALDH high population (Figure 5.6). To
elucidate whether this was under the control of ALDH1A3, I examined
expression of RXRG in the ALDH1A3-null cell line compared to
Cas9-expressing only cells. Interestingly, RXRG expression was not
perturbed upon removal of ALDH1A3 (Figure 5.6). Investigation of other
retinoic acid receptor genes revealed that RARB is expressed at lower levels
in ALDH1A3-null cells than ALDH1A3-proficient cells (Figure 5.6).
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Figure 5.6: Retinoic Acid Receptor Expression is Altered Under Different
ALDH States
Differential gene expression in ALDH high/low and
ALDHcas9/1A3-null cell lines. RXRG was one of the most
highly-abundant genes in the ALDH high population and
expression of the RARB receptor is altered upon ALDH1A3
depletion. Non significant genes are labelled in grey and have
P>0.05.
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5.2.4 ALDH1A3 Expression Enhances Abundance of
Retinoic Acid-Critical Transcripts
As ALDH1A3 protein is essential for ALDEFLUOR™ turnover and is the major
transcript expressed at the transcriptomic level in A375 cells (Figure 5.7), it
was hypothesised that the expression of retinoic acid genes would be under
control of ALDH1A3 and the same population of genes in ALDHhigh vs
ALDHlow and ALDH1A3 vs ALDH1A3-null populations would overlap. To
explore the overlap between genes that are differentially expressed in
ALDHhigh populations and upon removal of ALDH1A3 activity in the A375 cell
line, I compared which genes were shared between these populations (Figure
5.8). 20.5% of genes differentially expressed in ALDH high and low
populations are also differentially expressed in ALDH1A3-null A375 cells and
conversely, 33.8% of genes differentially expressed between ALDH1A3
expressing and non-expressing cells are differentially expressed between the
top and bottom 5% of ALDH-expressing cells. These 458 genes are enriched
for synaptic and neurodevelopmental genes and some are involved in the
retinoic acid response (AQP1, DUSP1,WNT7B, SOX9), this is also supported
with GO:term analysis which indicates that the response to retinoic acid
signalling is perturbed. This indicates that the retinoic acid gene expression
profile in melanoma is dependent upon ALDH1A3.
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Figure 5.7: ALDH1A3 is the Predominant ALDH Transcript Expressed in
the A375 Cell Line
Aldh isoforms are expressed within the A375 cell line and Aldh1a3
is the predominant of all 19 human isoforms. Error bars represent
standard deviation.
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Figure 5.8: GO Expression of Genes Which Are Commonly Differentially
Expressed in Both ALDH1A3high and ALDH1A3lowcells and
ALDH-Depleted Cell Lines
Differentially expressed genes in ALDH1A3high, ALDH1A3low and
ALDHcas9/1A3-null cell lines were compared to distinguish
common links between four populations that either have
ALDH1A3 expression or have low/no ALDH1A3 expression.
Overlapping genes were analysed against GO GSEA terms.
Gene categories are sorted by fold-change with FDR < 0.05 and
raw p-value <0.001.
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5.3 Summary
To decipher the contribution of ALDH1A3 expression to the characteristics of
ALDHhigh cells with tumour-initiating and chemoresistant properties,
transcriptional analysis of ALDH-proficient and ALDH-deficient cells was
performed. GSEA was performed to elucidate associated gene sets and
signaling pathways that were differentially expressed in different ALDH1A3
environments. A key transcriptional difference in melanoma cell populations
that exhibit differential expression of ALDH1A3 was identified. I have shown
that subpopulations differ in the expression of key genes responsible for
retinoic acid signalling, neural cell development and control over MITF, a
major melanocyte transcription factor.
I have found that ALDH-expressing cells, which have been shown to
develop resistance to traditional chemotherapies express genes which
underpin neural stem cell development and have been associated with
minimal residual disease in melanoma. Recently, Rambow et al. (2018)
investigated minimal residual disease which can be likened to the
tumour-initiating cancer cells that persist during chemotherapy treatment
(Figure 5.9. They found that expression of a core set of genes (NCSC
Rambow gene set Cluster) is a predictor of melanoma chemotherapeutic
resistance. This core set of genes is dependent upon RXRG expression and
can be controlled by administration of RXRG inhibitors, which is one of the
most statistically significant genes upregulated in the ALDHhigh
subpopulation I have characterised. Although ALDH1A3 is notorious for its
expression in the cancer-initiating cell and retinoic acid signalling through
RXR is dependent upon ALDH, the link between ALDH1A3 and the minimal
residual disease gene cluster identified by Rambow has not been made until
now. I propose that retinoic acid synthesis by ALDH1A3 bridges the link
between altered RXRG signalling to confer the NCSC state and the function
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Figure 5.9: RXRG induces the NCSC state following BRAF and MEK
inhibitor therapy
Exposure of melanoma to BRAF and MEK inhibitors causes cells
to become nutrient-deprived (“starved”-like melanoma cells,
SMC). Analysis of patient biopsies by Rambow et al. (2018)
revealed the NCSC was a predominant drug-tolerant state in
patients which were on therapy. Interrogation of the NCSC
signature revealed its similarity to both quiescent neural stem cells
and drug-persister signature in lung cancer. Image from Rambow
et al. (2018).
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of ALDH1A3 in promoting tumour-initiating and chemo-resistant properties in
melanoma (Figure 5.10). This is supported through my experimental finding
that the expression of genes involved in the Rambow NCSC minimal residual
disease cluster are differentially expressed in ALDH1A3 subpopulations and
that absence of ALDH activity alters the expression of key retinoic acid
receptor genes, RXRG and RARB. RXRG is activated by 9-cis-retinoic acid
which activates retinoic acid receptors (RAR) and retinoid X receptors (RXR)
receptors (Kane and Napoli, 2010). RAR is also activated by all-trans-retinoic
acid, which is a product of ALDH1A3 metabolism of All-trans-Retinaldehyde
(Table 1.1) (Kane and Napoli, 2010). This is relevant to the repurposing of
nifuroxazide as therapeutic option for melanoma treatment. It has been
established that nifuroxazide is selectively bioactivated in cells that express
high levels of ALDH (Sarvi et al., 2018) and so might have further potential for
the selective targeting of the NCSC state.
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Figure 5.10: ALDH1A3 as a Mediator of the NCSC State
Exposure of melanoma to BRAF and MEK inhibitors causes cells
to overexpress ALDH1A3 (Sarvi et al., 2018). Analysis of the
ALDHhigh population revealed cell-type specific expression of
NCSC genes, which is attributed to expression of the
RXRgamma receptor, of which the ALDH1A3 substrate,
retinaldehyde is a precursor.
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Conclusions and Future Directions
6.1 Conclusions
Throughout this thesis I have investigated the relevance of ALDH to two
biological questions that relate to gene-drug interactions between ALDH and
5-NFNs and ALDH signalling in melanoma. With an array of methodological
approaches, I have explored the downstream effects of 5-NFN exposure and
expression of ALDH isoforms in both somatic tissue and cancer cell contexts.
I have shown that mammalian ALDH enzymes are inhibited by 5-NFNs in vitro
and that crucially, the inhibitory effect of 5-NFN exposure on ALDH activity is
maintained in the PCLS ex vivo drug metabolism model. I demonstrate that
5-NFNs are cytotoxic in a liver-derived cell line and that 5-NFN and
acetaldehyde exposure drives synergistic effects in HepG2 cells. Critically,
through in vivo experiments in the Aldh1b1-deficient mouse line, I discovered
that short-term exposure to 5-NFNs drive accumulation of circulating levels of
acetaldehyde, indicating a novel route of 5-NFN toxicity. To enable future
quantification of acetaldehyde, I instigated the set up of HPLC methods to
quantify acetaldehyde concentrations in mouse plasma. I set up derivatisation
and LC-MS sample preparation approaches to stabilise and extract aldehydes
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from plasma matrices, identified diagnostic ions for acetaldehyde-DNPH with
LC-Triple-Quadrupole-MS/MS. As ALDH enzymes metabolise various
aldehydes, I followed three ALDH1B1/ALDH2 substrates (acetaldehyde,
propionaldehyde and formaldehyde) through chromatographic set up coupled
with high resolution accurate-mass Orbitrap-MS, to demonstrate the
opportunity for pan-measurement of ALDH1B1 and ALDH2 substrates in
plasma matrices. Finally, with an interest in identifying characteristics of
ALDH populations that are sensitive to the effects of 5-NFNs in melanoma, I
analysed the transcriptome of ALDH high and ALDH low populations in
melanoma. I discovered that these populations differ in the expression of key
genes that underlie retinoic acid metabolism but also that
ALDH1A3-dependent and independently-curated minimal residual disease
transcriptional profiles overlap. Collectively, these experiments demonstrate
the importance of aldehydes in mediating the downstream effects of ALDH
activity for both gene-drug interactions and cancer cell populations. However,
some experiments could explore the dynamics of these interactions further,
particularly when seeking to understand the contribution of genetic landscape
and environmental effects to mediation of these signals.
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6.2 Future Directions
6.2.1 Importance of Aldehydes in Mediating Cytotoxicity of
5-Nitrofurans and Minimal Residual Disease in
Melanoma
6.2.1.1 Aldehydes
I propose that the synergistic effects of coexposure to nitrofurans and
acetaldehyde are a result of dual targeting of the acetaldehyde-detoxification
pathway via ALDH enzymes (Figure 6.1). I show that ALDH1B1 is required for
detoxification of 5-NFN induced damage and propose that aldehydes arise as
a result of inhibition of ALDH enzymes. Given that ALDH1B1 has a propensity
for acetaldehyde metabolism, and shows preference for acetaldehyde as a
substrate (Stagos et al., 2010), it is unlikely that ALDH1B1 exerts these
protective functions through an additional mechanism. By initiating
development of new mass spectrometry methods, in two mass spectrometry
systems that allowed for robust detection but also pan-quantification of
aldehydes. I would hope to be able to pin point the exact repertoire of
aldehydes that accumulate during exposure to 5-nitrofurans. Such an
approach is ambitious, considering that multiple research groups have studied
aldehyde metabolism and usually report the analysis of a single aldehyde
(Dator et al., 2017). The suitability of DNPH as a derivatisation agent for the
study of aldehydes in plasma is subject to dispute due to background
aldehydes which present a route of contamination during derivatisation. That
said, data-dependent MSn methods have been employed for MS3 screening
of DNPH derivatives to detect unknown or unexpected carbonyls in saliva
(Dator et al., 2017). In addition, new tools employing quenched hydrazones
have potential to enable fluorescent tagging of aldehyde load, albeit in vitro
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(Yuen et al., 2016). Silva et al. (2018) have utilised a GC-high resolution MS
method to measure 19 aldehydes but acetaldehyde had the highest LOD by
more than 10X compared to the remaining 18 aldehydes measured, this is
surprising as GC-MS is well-suited to the analysis of volatile aldehydes.
6.2.1.2 Bioactivation of Nitrofurans and DNA-damage
It still remains to be shown what the individual effect of 5-nitrofuran
metabolites have on tissues in vivo. This would have an impact on the
understanding of 5-nitrofuran side effects and delineation of additional
underlying mechanisms but in terms of my experiments, would enable me to
pinpoint exactly which ALDHs in vivo are responsible for ALDH-mediated
bioactivation of 5-nitrofurans. I would test this through administration of stable
isotope-labelled 5-nitrofurans with and without ethanol to Aldh2- and
Aldh1b1-deficient mice. I would extract nitrofuran-metabolising tissues and
circulating plasma to trace accumulated 5-nitrofuran species with
high-resolution mass spectrometry that is well suited to discovery research.
Incidentally, a recently identified nitrofuran metabolite, 5-Nitro-2-furaldehyde
carries a carbonyl group and could itself be a potential substrate or inhibitor of
ALDH enzymes (Zhang et al., 2017).
203 Chapter 6
Aldehydes, gene-drug interactions and cancer subpopulations
Figure 6.1: Contribution of Acetaldehyde-Metabolism to 5-NFN
Cytotoxicity.
5-Nitrofuran-induced inhibition of acetaldehyde-metabolising
ALDH enzymes promotes accumulation of DNA-damaging
acetaldehyde and a reduction in acetate availability and promotes
cellular toxicity.
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I have shown that 5-NFNs depleted cell viability through the use of
PrestoBlue reagent. This reagent is widely-used for the analysis of cell
viability but is dependent on mitochondrial turnover of the substrate. As ALDH
is a mitochondrially-expressed protein, it is possible that nitrofurans alter the
mitochondrial capacity of the cell. I would test this further by using
mitochondrial oxidation markers such as pMitoTimer to enable live-tracking of
mitochondrial dynamics upon 5-nitrofuran exposure and delineation of the
fine-interplay between ROS, lipid peroxidation and aldehyde biology.
The impact of 5-nitrofurans on circulating aldehydes is interesting. Recently,
the important role of ALDH and components of DNA damage repair pathways
in aldehyde detoxification have been brought to the forefront (Lu et al., 2017;
Ray Chaudhuri and Nussenzweig, 2017). If protection through ALDH activity
is insufficient or non-existent, resulting aldehyde adducts on DNA and proteins
need to be resolved. DNA repair mechanisms can resolve metabolite inflicted
DNA damage.
In the haematopoietic stem cell, it has been shown that
formaldehyde-detoxifying ADH5, acetaldehyde- and formaldehyde-
detoxifying ALDH2 and Fanconi Anaemia component, FANCD2 genes are
key in preventing development of Fanconi Anaemia (Langevin et al., 2011).
These aldehyde detoxifying and DNA repair mechanisms are not
insurmountable, it has recently been demonstrated that homologous
recombination(HR)-compromised cells are hypersensitive to acetaldehyde
even with proficient FA pathway activity (Tacconi et al., 2017). Additionally,
BRCA-mediated homology-directed DNA repair mechanisms are susceptible
to the effects of formaldehyde. Aldehyde adducts on the DNA-repair enzyme,
BRCA2 that arise from exposure to formaldehyde and acetaldehyde have
been shown to target BRCA2 for proteasomal degradation (Lu et al., 2017).
This means that aldehydes have the capacity to not only induce DNA damage
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through destabilisation of DNA replication forks and resulting chromosomal
abberations but actively prevent DNA-damage repair mechanisms from
resolving aldehyde-induced damage. Acknowledging the importance of
maintaining genetic stability and that aldehydes present a metabolic challenge
to the cell, there is a need to further characterise chemical agents or cellular
events that could lead aldehyde levels to rise in the cell and alter cellular
homeostasis. To put a fresh stance on the effects of Aldh2 deficiency on
alcohol-associated cancers, Seo et al. (2019) investigated an ethanol-induced
propagation of oncogenic pathway signalling. As expected, administration of
ethanol in the carbon tetra-chloride-induced liver fibrosis model elevated
levels of MDA and 4-HNE in liver tumours in ALDH2-null mice, as well as
elevated phosphorylated STAT3, p28 and pJNK markers of oxidative stress.
Interestingly, they also demonstrated that oxidised mitochondrial DNA
(8-OhDG) is sequestered into extracellular vesicles and exogenous
administration of vesicles in HepG2 cell culture enhances the expression of
the oxidative stress markers. They suggest that this effect is synergistic with
acetaldehyde exposure, but in the absence of synergy analysis, whether
these effects are truly additive or synergistic is to be established. This aside,
these data comprise a signalling model where oncogenic pathways involving
ethanol and acetaldehyde-induced damage can be communicated to
neighbouring tumour cells. Given that acetaldehyde and 5-nitrofurans drive
synergistic cytotoxic effects, it would be reasonable to hypothesise that
carriers of the ALDH2*2 mutation could be more susceptible to the
acetaldehyde-inducing effects of 5-NFNs. Furthermore, 5-NFNs may be an
attractive option for the treatment of chemoresistant populations in cancer.
Chemoresistant cancer cell populations often exhibit impaired DNA-damage
repair (Sitthi-Amorn et al., 2015). By enhancing aldehyde levels systemically
with 5-NFNs, cells may be sensitised to the effects of chemotherapeutics. By
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administering 5-NFNs to melanoma patients with tumours harbouring the
NCSC signature, metabolism of the key retinoic acid drivers of RXRG
signalling would be hindered. To understand the molecular mechanism
underpinning the NCSC signature, delineation of retinoic acid receptors, their
activation by retinoic acid (all-trans-retinal or 9-cis-retinal) and the contribution
of ALDH1A3 to the metabolism of the retinaldehyde precursors needs to be
addressed. The susceptibility of retinoids to isomerisation and oxidation
presents a challenge for revealing the true substrates and products involved
in the RXRG signalling response (Kane and Napoli, 2010).
6.2.1.3 Functions of ALDH in Cancer-Initiating Cells
It was shown that 5-NFNs inhibit the esterase activity of ALDH enzymes in
a concentration-dependent manner. This is interesting because there are no
known endogenous esterase substrates of ALDH enzymes. This enzymatic
function could be evolutionarily redundant but there are no published screens
that have looked to identify esterase substrates. Additionally, NFN1 had the
most pronounced inhibitory effect on ALDH in cells and tissue and contains
an ester group that could be susceptible to ester hydrolysis. If endogenous
ester substrates of ALDH exist, this may have implications on metabolism of
a wide range of biologically active compounds. Notably, Zhong et al. (2019)
report that in the absense of ALDH2, cholesterol hydrolysis is impaired within
lysosomes and contributes to increased foam cell formation. It is intriguing to
hypothesise that ALDH contributes to metabolism of these compounds also
through it’s enzymatic ALDH activity.
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6.3 Concluding Remarks
The work that I have undertaken in this thesis has identified the molecular and
cellular consequences of a protein-drug interaction between ALDH and
5-NFNs. This work highlights mechanistically how ALDH:5-NFN interactions
lead to acetaldehyde accumulation following 5-NFN exposure, offering a
novel insight into the mechanism underpinning DNA-damage accumulation
and development of side effects upon exposure to 5-NFNs. My development
of derivatisation and HPLC-MS methods for aldehyde quantification sets the
stage for the analysis of multiple aldehydes in biological matrices to decipher
biological levels of aldehydes in vivo and the involvement of ALDH isoforms
and envionmental or endogenous agents in mediating these levels. Finally, I
have discovered that a critical chemotherapeutic-resistant population in
melanoma is governed by ALDH1A3 expression. As a whole, these advances
are important for understanding protein-drug and cell-specific-drug
interactions between ALDH enzymes and 5-nitrofurans.
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